'use client';

import React, { useState, useEffect } from 'react';
import { MainLayout } from '@/components/MainLayout';
import { Card } from '@/components/ui/card';
import { Input } from '@/components/ui/input';
import { Button } from '@/components/ui/button';

// Mock peptide data (in production, this would come from Supabase)
const PEPTIDES = [
  {
    id: '1',
    slug: 'bpc-157',
    name: 'BPC-157 (Body Protection Compound-157)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Gastric pentadecapeptide promoted online; human safety and efficacy remain unestablished.',
    mechanism: 'Preclinical studies suggest angiogenic and cytoprotective signaling that may influence wound and tendon repair; human pharmacology is uncertain.',
    evidence: [
      {
        title: 'USADA advisory on BPC-157',
        year: 2019,
        source: 'USADA',
        summary: 'Warning about BPC-157 use and anti-doping violations',
        url: 'https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/',
      },
    ],
    common_adverse_effects: 'Unknown; safety not established in controlled human trials',
    contraindications: 'Athletes: prohibited under anti-doping rules',
    recommended_dosage: '250-500 mcg daily, subcutaneous or intramuscular',
  },
  {
    id: '2',
    slug: 'tb-500',
    name: 'Thymosin Beta-4 / TB-500',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Actin-binding peptide explored in dermal and corneal healing models; human approvals lacking.',
    mechanism: 'Facilitates cell migration and angiogenesis; binds G-actin and modulates cytoskeletal dynamics in preclinical systems.',
    evidence: [
      {
        title: 'Thymosin β4 in tissue repair (review)',
        year: 2021,
        source: 'PMC',
        summary: 'Comprehensive review of Thymosin Beta-4 in tissue repair and regeneration',
        url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8228050/',
      },
    ],
    common_adverse_effects: 'Injection-site reactions (reported), Unknown long-term safety',
    contraindications: 'Malignancy caution (theoretical)',
    recommended_dosage: '2-2.5 mg twice weekly for loading phase, then 2 mg weekly for maintenance',
  },
  {
    id: '3',
    slug: 'cjc-1295',
    name: 'CJC-1295',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Longer-acting GHRH analog investigated for sustained GH/IGF-1 elevations.',
    mechanism: 'Stimulates pituitary somatotrophs via GHRH receptor; DAC variant prolongs exposure through albumin binding.',
    evidence: [
      {
        title: 'CJC-1295 human studies',
        year: 2006,
        source: 'PubMed',
        summary: 'Clinical investigation of CJC-1295 effects on GH secretion',
        url: 'https://pubmed.ncbi.nlm.nih.gov/16352683/',
      },
      {
        title: 'FDA: Safety risks (compounded peptides)',
        year: 2024,
        source: 'FDA',
        summary: 'FDA warning on compounded peptide safety',
        url: 'https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks',
      },
    ],
    common_adverse_effects: 'Injection site reactions, Flu-like symptoms (reported)',
    contraindications: 'Active malignancy (theoretical)',
    recommended_dosage: '1-2 mg per week, subcutaneous injection',
  },
  {
    id: '4',
    slug: 'ipamorelin',
    name: 'Ipamorelin',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Selective GHSR-1a agonist that triggers GH pulses with low ACTH/cortisol spillover in studies.',
    mechanism: 'Binds the ghrelin receptor to stimulate pituitary GH release with relative selectivity versus other pituitary axes.',
    evidence: [
      {
        title: 'Ipamorelin selectivity (foundational study)',
        year: 1998,
        source: 'PubMed',
        summary: 'Characterization of ipamorelin mechanism',
        url: 'https://pubmed.ncbi.nlm.nih.gov/9849822/',
      },
      {
        title: 'FDA: Safety risks with certain compounded peptides',
        year: 2024,
        source: 'FDA',
        summary: 'FDA warning on compounded peptide safety',
        url: 'https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks',
      },
    ],
    common_adverse_effects: 'Headache, Flushing, Dizziness (reported)',
    contraindications: 'Active malignancy (theoretical)',
    recommended_dosage: '200-300 mcg 2-3 times daily, subcutaneous',
  },
  {
    id: '5',
    slug: 'selank',
    name: 'Selank',
    regulatory_status: 'Research-only/Unapproved (US)',
    summary: 'Heptapeptide derived from the immune peptide tuftsin; explored for anxiolytic and cognitive effects.',
    mechanism: 'May modulate GABAergic signaling and neurotrophic pathways; exact pharmacology remains under study.',
    evidence: [
      {
        title: 'Tuftsin-derived peptides and neurobiology (review)',
        year: 2016,
        source: 'PubMed',
        summary: 'Review of Selank and related peptides in neurobiology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/27803462/',
      },
    ],
    common_adverse_effects: 'Limited controlled data; nasal irritation reported anecdotally',
    contraindications: 'Unknown',
    recommended_dosage: '250-500 mcg intranasal or subcutaneous, 1-3 times daily',
  },
  {
    id: '6',
    slug: 'semax',
    name: 'Semax',
    regulatory_status: 'Research-only/Unapproved (US)',
    summary: 'Neuropeptide analog investigated for cognitive and neurotrophic effects in regional studies.',
    mechanism: 'Proposed modulation of BDNF expression and neurotransmission; precise targets remain under investigation.',
    evidence: [
      {
        title: 'Semax experimental studies (overview)',
        year: 2016,
        source: 'PubMed',
        summary: 'Overview of Semax research and mechanisms',
        url: 'https://pubmed.ncbi.nlm.nih.gov/27078861/',
      },
    ],
    common_adverse_effects: 'Limited controlled data; nasal irritation reported in some reports',
    contraindications: 'Unknown; seizure disorders warrant caution in research',
    recommended_dosage: '300-600 mcg intranasal, 1-2 times daily',
  },
  {
    id: '7',
    slug: 'ghk-cu',
    name: 'GHK-Cu (Copper Peptide)',
    regulatory_status: 'Research-only / Cosmetic use',
    summary: 'A copper-binding peptide studied for skin regeneration and anti-aging properties.',
    mechanism: 'Stimulates collagen and glycosaminoglycan synthesis, promotes wound healing and angiogenesis',
    evidence: [
      {
        title: 'Regenerative and Protective Effects of GHK-Cu',
        year: 2018,
        source: 'Biomedicine & Pharmacotherapy',
        summary: 'Comprehensive review of regenerative mechanisms',
      },
    ],
    common_adverse_effects: 'Mild skin irritation when applied topically',
    contraindications: "Wilson's disease, copper sensitivity",
    recommended_dosage: '1-3 mg subcutaneous or topical application',
  },
  {
    id: '8',
    slug: 'melanotan-ii',
    name: 'Melanotan II',
    regulatory_status: 'Research-only',
    summary: 'A synthetic peptide analog studied for pigmentation and other metabolic effects.',
    mechanism: 'Melanocortin receptor agonist affecting pigmentation, appetite, and sexual function',
    evidence: [
      {
        title: 'Melanocortin Receptor Agonists',
        year: 2014,
        source: 'Journal of Clinical Investigation',
        summary: 'Mechanisms of melanocortin signaling',
      },
    ],
    common_adverse_effects: 'Nausea, facial flushing, increased libido, darkening of moles',
    contraindications: 'Melanoma history, uncontrolled hypertension, pregnancy',
    recommended_dosage: '250-500 mcg 2-3 times weekly, subcutaneous',
  },
  {
    id: '9',
    slug: 'epithalon',
    name: 'Epithalon (Epitalon)',
    regulatory_status: 'Research-only',
    summary: 'A peptide studied for its potential anti-aging and telomerase-activating properties.',
    mechanism: 'Potential telomerase activation, melatonin regulation, antioxidant effects',
    evidence: [
      {
        title: 'Peptide Regulation of Aging',
        year: 2003,
        source: 'Biogerontology',
        summary: 'Studies on peptide bioregulation',
      },
    ],
    common_adverse_effects: 'Rare: mild fatigue, drowsiness',
    contraindications: 'Pregnancy, active malignancy',
    recommended_dosage: '5-10 mg for 10-20 days, 1-2 cycles per year',
  },
  {
    id: '10',
    slug: 'pt-141',
    name: 'PT-141 (Bremelanotide)',
    regulatory_status: 'FDA-approved for female sexual dysfunction',
    summary: 'A melanocortin receptor agonist approved for hypoactive sexual desire disorder.',
    mechanism: 'Activates melanocortin receptors in CNS affecting sexual arousal pathways',
    evidence: [
      {
        title: 'Bremelanotide for Hypoactive Sexual Desire Disorder',
        year: 2019,
        source: 'NEJM',
        summary: 'Phase 3 clinical trial results',
      },
    ],
    common_adverse_effects: 'Nausea, flushing, headache, vomiting',
    contraindications: 'Uncontrolled hypertension, cardiovascular disease, pregnancy',
    recommended_dosage: '1.75 mg subcutaneous as needed, max once per 24 hours',
  },
  {
    id: '11',
    slug: 'ghrp-6',
    name: 'GHRP-6',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Legacy growth-hormone secretagogue studied for GH pulses and appetite effects.',
    mechanism: 'Agonizes the ghrelin (GHSR-1a) receptor on pituitary and hypothalamic targets, increasing pulsatile GH release and engaging appetite pathways.',
    evidence: [
      {
        title: 'Growth hormone secretagogues and ghrelin receptor',
        year: 2009,
        source: 'PubMed',
        summary: 'Overview of GHRP-6 and ghrelin receptor mechanisms',
        url: 'https://pubmed.ncbi.nlm.nih.gov/19133992/',
      },
    ],
    common_adverse_effects: 'Hunger sensations (reported in studies), Flushing, Headache',
    contraindications: 'Active malignancy (theoretical concern with GH/IGF-1 pathways)',
    recommended_dosage: 'Research protocols vary; no approved dosing',
  },
  {
    id: '12',
    slug: 'follistatin-344',
    name: 'Follistatin 344',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Glycoprotein domain/peptide that binds activins and myostatin, altering muscle signaling in models.',
    mechanism: 'Sequesters activins/myostatin, decreasing SMAD-mediated signaling that suppresses muscle growth.',
    evidence: [
      {
        title: 'Follistatin and muscle growth review',
        year: 2008,
        source: 'PubMed',
        summary: 'Review of follistatin role in muscle biology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/19038649/',
      },
    ],
    common_adverse_effects: 'Unknown human safety profile',
    contraindications: 'Oncologic caution (theoretical growth signaling)',
    recommended_dosage: 'No established human dosing',
  },
  {
    id: '13',
    slug: 'll-37',
    name: 'LL-37',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Human cathelicidin fragment with antimicrobial and immune-modulating actions; studied in wound and infection models.',
    mechanism: 'Disrupts microbial membranes and modulates innate immune responses including chemotaxis and cytokine release.',
    evidence: [
      {
        title: 'LL-37: biology and therapeutic potential (review)',
        year: 2013,
        source: 'PMC',
        summary: 'Comprehensive review of LL-37 antimicrobial and immune functions',
        url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3658991/',
      },
    ],
    common_adverse_effects: 'Topical irritation reported in studies',
    contraindications: 'Auto-inflammatory skin conditions (caution, context-dependent)',
    recommended_dosage: 'Topical applications in research; no standardized dosing',
  },
  {
    id: '14',
    slug: 'mots-c',
    name: 'MOTS-c',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Small peptide encoded by mitochondrial DNA implicated in metabolic and exercise responses.',
    mechanism: 'Appears to activate AMPK-linked stress pathways and improve metabolic flexibility in preclinical models.',
    evidence: [
      {
        title: 'MOTS-c overview (review)',
        year: 2019,
        source: 'Frontiers in Endocrinology',
        summary: 'Overview of MOTS-c as mitochondrial-derived peptide',
        url: 'https://www.frontiersin.org/articles/10.3389/fendo.2019.00553/full',
      },
    ],
    common_adverse_effects: 'Unknown human safety profile',
    contraindications: 'Unknown; metabolic disorders warrant caution in trials',
    recommended_dosage: 'No established human dosing',
  },
  {
    id: '15',
    slug: 'humanin',
    name: 'Humanin',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Endogenous peptide reported to exert cytoprotective effects in models of neurodegeneration and metabolism.',
    mechanism: 'Interacts with cell-surface and intracellular targets (e.g., FPRL1/2, IGFBP3 pathways) to reduce apoptotic signaling in stress contexts.',
    evidence: [
      {
        title: 'Humanin and mitochondrial-derived peptides (review)',
        year: 2017,
        source: 'PMC',
        summary: 'Review of humanin and related mitochondrial peptides',
        url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5671641/',
      },
    ],
    common_adverse_effects: 'Unknown in humans',
    contraindications: 'Unknown',
    recommended_dosage: 'No established human dosing',
  },
  {
    id: '16',
    slug: 'epitalon',
    name: 'Epitalon',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Short peptide linked to circadian/aging biology in preclinical literature; human evidence remains limited.',
    mechanism: 'Proposed modulation of melatonin rhythms and telomerase activity in vitro; in vivo mechanisms are debated.',
    evidence: [
      {
        title: 'Pineal peptides and aging (overview)',
        year: 2015,
        source: 'PubMed',
        summary: 'Overview of pineal peptides including Epitalon in aging research',
        url: 'https://pubmed.ncbi.nlm.nih.gov/25824742/',
      },
    ],
    common_adverse_effects: 'Unknown; small studies report minimal acute effects',
    contraindications: 'Unknown',
    recommended_dosage: '5-10 mg for 10-20 days, 1-2 cycles per year (research protocols)',
  },
  {
    id: '17',
    slug: 'kpv',
    name: 'KPV (α-MSH 11-13)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Small α-MSH fragment investigated for anti-inflammatory effects in gut and skin models.',
    mechanism: 'Engages melanocortin-linked anti-inflammatory signaling and may be transported by PepT1 in the gut.',
    evidence: [
      {
        title: 'KPV anti-inflammatory activity',
        year: 2007,
        source: 'PMC',
        summary: 'Study of KPV anti-inflammatory properties',
        url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/',
      },
    ],
    common_adverse_effects: 'Insufficient human data',
    contraindications: 'Unknown',
    recommended_dosage: 'No established human dosing',
  },
  {
    id: '18',
    slug: 'foxo4-dri',
    name: 'FOXO4-DRI',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Designed peptide reported to disrupt FOXO4-p53 interactions in senescent cells, promoting their apoptosis in models.',
    mechanism: 'Interferes with FOXO4 binding to p53, tipping senescent cells toward programmed cell death in preclinical systems.',
    evidence: [
      {
        title: 'Targeting senescent cells via FOXO4-p53 (foundational study)',
        year: 2017,
        source: 'PubMed',
        summary: 'Foundational study on FOXO4-DRI as senolytic agent',
        url: 'https://pubmed.ncbi.nlm.nih.gov/28340339/',
      },
    ],
    common_adverse_effects: 'Unknown in humans',
    contraindications: 'Unknown',
    recommended_dosage: 'No established human dosing',
  },
  {
    id: '19',
    slug: 'thymosin-alpha-1',
    name: 'Thymosin Alpha-1',
    regulatory_status: 'Research-only/Unapproved (US)',
    summary: 'Immune-modulating peptide with regional approvals outside the US; explored for infectious and oncologic contexts.',
    mechanism: 'Augments T-cell maturation and function, influences dendritic cells, and modulates innate immunity.',
    evidence: [
      {
        title: 'Thymosin alpha-1: immunology and clinical evidence (review)',
        year: 2018,
        source: 'PMC',
        summary: 'Review of Thymosin alpha-1 immunology and clinical applications',
        url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5775641/',
      },
    ],
    common_adverse_effects: 'Injection-site reactions reported in studies outside US',
    contraindications: 'Autoimmune flares (theoretical caution)',
    recommended_dosage: 'Varies by regional protocols; no US approval',
  },
  {
    id: '20',
    slug: 'hexarelin',
    name: 'Hexarelin',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Potent synthetic GH secretagogue used to probe GH pulse dynamics.',
    mechanism: 'Activates GHSR-1a on pituitary/hypothalamus to increase pulsatile GH release; may desensitize with chronic exposure in models.',
    evidence: [
      {
        title: 'GHSR agonists and GH secretion (review)',
        year: 2009,
        source: 'PubMed',
        summary: 'Review of ghrelin receptor agonists and GH secretion',
        url: 'https://pubmed.ncbi.nlm.nih.gov/19133992/',
      },
    ],
    common_adverse_effects: 'Flushing, Headache, Transient fatigue (reported)',
    contraindications: 'Active malignancy (theoretical GH/IGF-1 concerns)',
    recommended_dosage: 'Research protocols vary; no approved dosing',
  },
  {
    id: '21',
    slug: 'ghrp-2',
    name: 'GHRP-2 (Pralmorelin)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Early ghrelin mimetic used in diagnostic and physiology studies.',
    mechanism: 'Agonizes GHSR-1a to acutely increase GH; may influence hunger pathways via hypothalamus.',
    evidence: [
      {
        title: 'Diagnostic GH stimulation with GHRP-2',
        year: 2002,
        source: 'PubMed',
        summary: 'Study on GHRP-2 use in diagnostic GH stimulation',
        url: 'https://pubmed.ncbi.nlm.nih.gov/12050250/',
      },
    ],
    common_adverse_effects: 'Flushing, Headache, Hunger sensations (reported)',
    contraindications: 'Active malignancy (theoretical)',
    recommended_dosage: 'Research protocols vary; no approved dosing',
  },
  {
    id: '22',
    slug: 'mod-grf-1-29',
    name: 'Mod GRF (1-29)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Short-acting GHRH analog engineered for improved stability over native GHRH(1-29).',
    mechanism: 'Stimulates GHRH receptors on somatotrophs to enhance physiologic GH pulsatility; shorter exposure vs DAC-modified forms.',
    evidence: [
      {
        title: 'GHRH analogs and pulsatile GH secretion',
        year: 2006,
        source: 'PubMed',
        summary: 'Study of GHRH analogs and their effects on GH secretion patterns',
        url: 'https://pubmed.ncbi.nlm.nih.gov/17018654/',
      },
    ],
    common_adverse_effects: 'Injection site reactions (reported)',
    contraindications: 'Active malignancy (theoretical)',
    recommended_dosage: 'Research protocols vary; no approved dosing',
  },
  {
    id: '23',
    slug: 'kisspeptin-10',
    name: 'Kisspeptin-10',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Fragment of kisspeptin used to study GnRH/LH axis activation.',
    mechanism: 'Stimulates hypothalamic GnRH neurons, increasing pituitary LH/FSH secretion in physiological studies.',
    evidence: [
      {
        title: 'Kisspeptin and human reproductive axis',
        year: 2005,
        source: 'PubMed',
        summary: 'Study of kisspeptin role in reproductive endocrinology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/15774510/',
      },
    ],
    common_adverse_effects: 'Flushing, Nausea (occasionally reported)',
    contraindications: 'Hormone-sensitive conditions (research caution)',
    recommended_dosage: 'Research protocols vary; no approved dosing',
  },
  {
    id: '24',
    slug: 'peptide-yy-3-36',
    name: 'Peptide YY (3-36)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Anorexigenic gut peptide fragment studied for appetite and energy balance.',
    mechanism: 'Preferential Y2 receptor agonist that suppresses appetite signals via hypothalamic pathways.',
    evidence: [
      {
        title: 'PYY(3-36) reduces appetite in humans',
        year: 2003,
        source: 'PubMed',
        summary: 'Study showing appetite-suppressing effects of PYY(3-36)',
        url: 'https://pubmed.ncbi.nlm.nih.gov/12915404/',
      },
    ],
    common_adverse_effects: 'Nausea (common in infusion studies)',
    contraindications: 'GI motility disorders (research caution)',
    recommended_dosage: 'Research infusion protocols; no approved dosing',
  },
  {
    id: '25',
    slug: 'angiotensin-1-7',
    name: 'Angiotensin (1-7)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Counter-regulatory RAS peptide with vasodilatory, anti-fibrotic signals in models.',
    mechanism: 'Activates Mas receptor to oppose Ang II–mediated vasoconstriction and fibrosis; explored in cardio-renal-pulmonary research.',
    evidence: [
      {
        title: 'Angiotensin-(1-7) and the Mas receptor (review)',
        year: 2008,
        source: 'PubMed',
        summary: 'Review of Angiotensin-(1-7) protective effects',
        url: 'https://pubmed.ncbi.nlm.nih.gov/18391159/',
      },
    ],
    common_adverse_effects: 'Insufficient human safety data',
    contraindications: 'Unknown',
    recommended_dosage: 'Research protocols vary; no approved dosing',
  },
  {
    id: '26',
    slug: 'vip',
    name: 'VIP (Vasoactive Intestinal Peptide)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Endogenous peptide with vasodilatory and anti-inflammatory actions; investigated in lung and immune research.',
    mechanism: 'Activates VPAC1/VPAC2 G-protein receptors, raising cAMP and relaxing smooth muscle while modulating cytokines.',
    evidence: [
      {
        title: 'VIP biology and therapeutic prospects (review)',
        year: 2011,
        source: 'PubMed',
        summary: 'Review of VIP biological functions and therapeutic potential',
        url: 'https://pubmed.ncbi.nlm.nih.gov/21947958/',
      },
    ],
    common_adverse_effects: 'Flushing, Headache (reported in physiology studies)',
    contraindications: 'Unknown',
    recommended_dosage: 'Research protocols vary; no approved dosing',
  },
  {
    id: '27',
    slug: 'pacap-38',
    name: 'PACAP-38',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Neuropeptide implicated in migraine provocation and neuroprotection research.',
    mechanism: 'Binds PAC1 and VPAC receptors to increase cAMP; induces vasodilation and CGRP-linked pathways relevant to headache biology.',
    evidence: [
      {
        title: 'PACAP and migraine induction in humans',
        year: 2017,
        source: 'PubMed',
        summary: 'Study on PACAP role in migraine induction',
        url: 'https://pubmed.ncbi.nlm.nih.gov/28153889/',
      },
    ],
    common_adverse_effects: 'Headache in provocation studies',
    contraindications: 'Migraine disorders (research caution)',
    recommended_dosage: 'Research protocols; not for therapeutic use',
  },
  {
    id: '28',
    slug: 'oxytocin',
    name: 'Oxytocin (research use)',
    regulatory_status: 'Compounded (not FDA-approved for behavioral indications)',
    summary: 'Endogenous peptide explored intranasally for social, stress, and feeding behaviors; obstetric use is distinct.',
    mechanism: 'Acts on oxytocin receptors in smooth muscle and CNS circuits that modulate social salience, bonding, and anxiety.',
    evidence: [
      {
        title: 'Intranasal oxytocin in human social cognition (review)',
        year: 2019,
        source: 'PubMed',
        summary: 'Review of intranasal oxytocin effects on social cognition',
        url: 'https://pubmed.ncbi.nlm.nih.gov/31279672/',
      },
    ],
    common_adverse_effects: 'Nasal irritation, Headache (reported)',
    contraindications: 'Pregnancy/lactation (context-dependent clinical cautions)',
    recommended_dosage: 'Research protocols vary; no approval for behavioral use',
  },
  {
    id: '29',
    slug: 'arginine-vasopressin',
    name: 'Arginine Vasopressin (AVP)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Antidiuretic peptide used in physiology studies of water balance and vascular tone.',
    mechanism: 'Activates V2 receptors in kidney collecting ducts to increase water reabsorption; V1 receptors mediate vasoconstriction.',
    evidence: [
      {
        title: 'Vasopressin receptors and physiology (review)',
        year: 2001,
        source: 'PubMed',
        summary: 'Review of vasopressin receptor biology and physiology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/11359618/',
      },
    ],
    common_adverse_effects: 'Headache, Nausea in research exposures',
    contraindications: 'Unknown',
    recommended_dosage: 'Research protocols only; controlled administration',
  },
  {
    id: '30',
    slug: 'afamelanotide',
    name: 'Afamelanotide (SCENESSE)',
    regulatory_status: 'FDA-approved',
    summary: 'Synthetic α-MSH analog approved in the US for erythropoietic protoporphyria (EPP) to increase pain-free light exposure.',
    mechanism: 'Agonizes MC1R to increase eumelanin, enhancing photoprotection and reducing phototoxic reactions in EPP.',
    evidence: [
      {
        title: 'FDA Approval Summary: Afamelanotide for EPP',
        year: 2020,
        source: 'PubMed',
        summary: 'FDA approval summary for afamelanotide in EPP treatment',
        url: 'https://pubmed.ncbi.nlm.nih.gov/32458570/',
      },
    ],
    common_adverse_effects: 'Nausea, Headache, Hyperpigmentation at implant site (reported)',
    contraindications: 'History of melanoma/atypical nevi (clinical caution)',
    recommended_dosage: 'Subcutaneous implant per FDA-approved protocol',
  },
  {
    id: '31',
    slug: 'thymopentin',
    name: 'Thymopentin (TP-5)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Short peptide from thymopoietin studied for T-cell modulation and immune maturation.',
    mechanism: 'Mimics a thymopoietin domain to influence T-cell differentiation and function.',
    evidence: [
      {
        title: 'Thymopentin and immune modulation (review)',
        year: 2011,
        source: 'PubMed',
        summary: 'Review of thymopentin immunomodulatory properties',
        url: 'https://pubmed.ncbi.nlm.nih.gov/21910519/',
      },
    ],
    common_adverse_effects: 'Injection-site reactions reported in historical studies',
    contraindications: 'Unknown',
    recommended_dosage: 'Research protocols vary; no US approval',
  },
  {
    id: '32',
    slug: 'bradykinin',
    name: 'Bradykinin',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Inflammatory/vasodilatory peptide used to probe vascular permeability and pain pathways.',
    mechanism: 'Activates B2 (and B1 under inflammation) receptors causing vasodilation, increased permeability, and nociception.',
    evidence: [
      {
        title: 'Kallikrein–kinin system in health and disease (review)',
        year: 2001,
        source: 'PubMed',
        summary: 'Review of kallikrein-kinin system biology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/11223758/',
      },
    ],
    common_adverse_effects: 'Pain, flushing in provocation models',
    contraindications: 'Unknown',
    recommended_dosage: 'Research provocation models only',
  },
  {
    id: '33',
    slug: 'endothelin-1',
    name: 'Endothelin-1 (ET-1)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Potent vasoconstrictor peptide used in cardiovascular physiology and endothelial function studies.',
    mechanism: 'Activates ETA/ETB receptors on vascular smooth muscle and endothelium to regulate tone and remodeling.',
    evidence: [
      {
        title: 'Endothelin system in cardiovascular disease (review)',
        year: 2002,
        source: 'PubMed',
        summary: 'Review of endothelin system in cardiovascular pathophysiology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/11997486/',
      },
    ],
    common_adverse_effects: 'Headache, BP changes in provocation models',
    contraindications: 'Unknown',
    recommended_dosage: 'Research provocation protocols only',
  },
  {
    id: '34',
    slug: 'urocortin-2',
    name: 'Urocortin-2',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Member of the corticotropin-releasing factor family studied for inotropy and vasodilation in heart failure research.',
    mechanism: 'Selectively activates CRF2 receptors, enhancing myocardial contractility and causing vasodilation in models.',
    evidence: [
      {
        title: 'Urocortin-2 in cardiac function (overview)',
        year: 2010,
        source: 'PubMed',
        summary: 'Overview of urocortin-2 cardiovascular effects',
        url: 'https://pubmed.ncbi.nlm.nih.gov/20451544/',
      },
    ],
    common_adverse_effects: 'Flushing, headache in small physiology studies',
    contraindications: 'Unknown',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '35',
    slug: 'aod-9604',
    name: 'AOD-9604',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'C-terminal fragment of human growth hormone marketed online for weight loss claims; not FDA-approved.',
    mechanism: 'Proposed to influence adipocyte lipolysis pathways without classic GH receptor activity; most evidence is preclinical and heterogeneous.',
    evidence: [
      {
        title: 'FDA: Certain bulk drug substances may present significant safety risks',
        year: 2024,
        source: 'FDA',
        summary: 'FDA warning on compounded peptide safety risks',
        url: 'https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks',
      },
      {
        title: 'GH fragments and metabolism (overview)',
        year: 2013,
        source: 'PubMed',
        summary: 'Overview of growth hormone fragments in metabolic research',
        url: 'https://pubmed.ncbi.nlm.nih.gov/24195643/',
      },
    ],
    common_adverse_effects: 'Unknown; non-standardized products raise identity and immunogenicity concerns',
    contraindications: 'Unknown safety; avoid assuming GH-class effects are absent',
    recommended_dosage: 'No approved dosing; research protocols vary',
  },
  {
    id: '36',
    slug: 'pnc-27',
    name: 'PNC-27',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Controversial experimental peptide reported to target tumor cell membranes in vitro; clinical evidence is limited.',
    mechanism: 'Designed to bind HDM2 on cancer cell membranes and disrupt mitochondrial integrity in preclinical models; selectivity in humans is unproven.',
    evidence: [
      {
        title: 'Peptide–mitochondrial interactions in cancer (review)',
        year: 2018,
        source: 'PubMed',
        summary: 'Review of peptide interactions with mitochondria in cancer research',
        url: 'https://pubmed.ncbi.nlm.nih.gov/30355731/',
      },
    ],
    common_adverse_effects: 'Unknown; not evaluated in rigorous clinical programs',
    contraindications: 'Do not infer anticancer benefit without trials',
    recommended_dosage: 'No established dosing; highly experimental',
  },
  {
    id: '37',
    slug: 'substance-p',
    name: 'Substance P',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Endogenous neuropeptide involved in pain transmission, neurogenic inflammation, and vasodilation; widely used in experimental models.',
    mechanism: 'Binds neurokinin-1 (NK1) receptors on neurons, endothelial cells, and immune cells, promoting nociception, vasodilation, and plasma extravasation.',
    evidence: [
      {
        title: 'Substance P and the NK1 receptor (review)',
        year: 2001,
        source: 'PubMed',
        summary: 'Review of Substance P and NK1 receptor biology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/11207144/',
      },
    ],
    common_adverse_effects: 'Provokes pain/flush in provocation paradigms',
    contraindications: 'Research use only; not for therapeutic administration',
    recommended_dosage: 'Research provocation protocols only',
  },
  {
    id: '38',
    slug: 'galanin',
    name: 'Galanin',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Neuromodulatory peptide implicated in feeding, pain, mood, and neuroendocrine regulation; a versatile tool in systems neuroscience.',
    mechanism: 'Signals via GAL1/2/3 receptors, modulating neurotransmitter release and neuronal excitability in hypothalamic and limbic circuits.',
    evidence: [
      {
        title: 'Galanin systems in the brain (review)',
        year: 2012,
        source: 'PubMed',
        summary: 'Review of galanin neurobiology and functions',
        url: 'https://pubmed.ncbi.nlm.nih.gov/22713167/',
      },
    ],
    common_adverse_effects: 'Not a therapeutic entry; adverse effects are model-dependent',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '39',
    slug: 'angiotensin-ii',
    name: 'Angiotensin II',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Canonical RAS vasoconstrictor used to probe blood pressure control, renal perfusion, and baroreflex physiology.',
    mechanism: 'Binds AT1 receptors to induce vasoconstriction, aldosterone release, sodium retention, and sympathetic facilitation; AT2 actions may oppose some effects.',
    evidence: [
      {
        title: 'Renin–angiotensin system: physiology and pathophysiology (review)',
        year: 2007,
        source: 'PubMed',
        summary: 'Comprehensive review of RAS physiology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/18083914/',
      },
    ],
    common_adverse_effects: 'Headache, BP elevation in provocation studies',
    contraindications: 'Hypertension/CV risk in non-research settings',
    recommended_dosage: 'Research provocation protocols only',
  },
  {
    id: '40',
    slug: 'gdf11-peptides',
    name: 'GDF11-related peptides',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Peptidic fragments associated with GDF11 signaling studied in aging and regeneration models; findings are controversial.',
    mechanism: 'Hypothesized modulation of SMAD/TGF-β pathways influencing neurogenesis and cardiac/skeletal muscle remodeling in animals.',
    evidence: [
      {
        title: 'GDF11 in aging and regeneration (perspective)',
        year: 2016,
        source: 'PubMed',
        summary: 'Perspective on GDF11 controversies in aging research',
        url: 'https://pubmed.ncbi.nlm.nih.gov/27452948/',
      },
    ],
    common_adverse_effects: 'Unknown; variable by construct',
    contraindications: 'Not a therapeutic; evidence is unsettled',
    recommended_dosage: 'Highly experimental; no established protocols',
  },
  {
    id: '41',
    slug: 'b7-33',
    name: 'B7-33',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Single-chain relaxin analog engineered to engage RXFP1 with reduced off-target effects; explored for anti-fibrotic signaling.',
    mechanism: 'Partial RXFP1 agonist activity reported in models, promoting anti-fibrotic and vasodilatory pathways while minimizing hypotension risk vs native relaxin.',
    evidence: [
      {
        title: 'B7-33, a relaxin-2 analog with anti-fibrotic actions',
        year: 2015,
        source: 'PubMed',
        summary: 'Study of B7-33 anti-fibrotic properties',
        url: 'https://pubmed.ncbi.nlm.nih.gov/25687646/',
      },
    ],
    common_adverse_effects: 'Unknown in humans',
    contraindications: 'Unknown',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '42',
    slug: 'palmitoyl-tripeptide-1',
    name: 'Palmitoyl Tripeptide-1 (Pal-GHK)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Topical cosmetic peptide derived from GHK, coupled to palmitic acid to enhance skin penetration; used in anti-aging formulations.',
    mechanism: 'Proposed to signal fibroblasts to support collagen matrix maintenance and repair; evidence primarily cosmetic/preclinical.',
    evidence: [
      {
        title: 'Topical peptides in anti-aging: review',
        year: 2013,
        source: 'PubMed',
        summary: 'Review of topical anti-aging peptides',
        url: 'https://pubmed.ncbi.nlm.nih.gov/24301263/',
      },
    ],
    common_adverse_effects: 'Topical irritation possible, formulation-dependent',
    contraindications: 'Copper allergy not directly relevant here (parent GHK-Cu differs)',
    recommended_dosage: 'Topical application per cosmetic formulations',
  },
  {
    id: '43',
    slug: 'palmitoyl-tetrapeptide-7',
    name: 'Palmitoyl Tetrapeptide-7',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Cosmetic peptide reported to modulate inflammatory signaling in skin; often combined with Pal-Tripeptide-1.',
    mechanism: 'Proposed to reduce pro-inflammatory cytokine signaling in dermis; evidence base is mostly cosmetic/preclinical.',
    evidence: [
      {
        title: 'Anti-inflammatory cosmetic peptides (overview)',
        year: 2020,
        source: 'PubMed',
        summary: 'Overview of anti-inflammatory peptides in cosmetics',
        url: 'https://pubmed.ncbi.nlm.nih.gov/32036743/',
      },
    ],
    common_adverse_effects: 'Potential topical irritation depending on vehicle',
    contraindications: 'None specific; patch testing advisable in studies',
    recommended_dosage: 'Topical application per cosmetic formulations',
  },
  {
    id: '44',
    slug: 'palmitoyl-pentapeptide-4',
    name: 'Palmitoyl Pentapeptide-4 (Matrixyl)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Widely cited cosmetic peptide claimed to support collagen renewal; used in anti-wrinkle formulations.',
    mechanism: 'Pentapeptide sequence derived from collagen fragments, proposed to signal ECM repair; palmitoylation improves topical delivery.',
    evidence: [
      {
        title: 'Topical anti-aging peptides: mechanisms and evidence',
        year: 2008,
        source: 'PubMed',
        summary: 'Study of topical anti-aging peptide mechanisms',
        url: 'https://pubmed.ncbi.nlm.nih.gov/18492053/',
      },
    ],
    common_adverse_effects: 'Topical irritation uncommon but possible',
    contraindications: 'None specific; cosmetic context',
    recommended_dosage: 'Topical application per cosmetic formulations',
  },
  {
    id: '45',
    slug: 'thymulin',
    name: 'Thymulin (Facteur Thymique Sérique)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Historic thymic peptide studied for T-cell function and immune maturation; interest persists in basic immunology.',
    mechanism: 'Influences T-cell differentiation and thymic epithelial interactions; precise receptor pharmacology remains incompletely defined.',
    evidence: [
      {
        title: 'Thymic peptides and immune function (overview)',
        year: 2006,
        source: 'PubMed',
        summary: 'Overview of thymic peptides in immune regulation',
        url: 'https://pubmed.ncbi.nlm.nih.gov/17145131/',
      },
    ],
    common_adverse_effects: 'Unknown in modern clinical contexts',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols vary; no US approval',
  },
  {
    id: '46',
    slug: 'carnosine',
    name: 'Carnosine',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Endogenous dipeptide concentrated in skeletal muscle and brain; studied for buffering and carbonyl-scavenging roles.',
    mechanism: 'Buffers intracellular pH during high-intensity activity and can scavenge reactive carbonyl species; interacts with metal ions.',
    evidence: [
      {
        title: 'Carnosine in exercise and aging (review)',
        year: 2016,
        source: 'PubMed',
        summary: 'Review of carnosine role in exercise and aging',
        url: 'https://pubmed.ncbi.nlm.nih.gov/26891120/',
      },
    ],
    common_adverse_effects: 'Oral/topical research generally well tolerated in small studies',
    contraindications: 'None specific in research contexts',
    recommended_dosage: 'Supplement/research dosing varies; not a drug',
  },
  {
    id: '47',
    slug: 'uroguanylin',
    name: 'Uroguanylin',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Endogenous intestinal peptide that activates guanylate cyclase-C (GC-C), regulating fluid/electrolyte transport and satiety circuits.',
    mechanism: 'Binds GC-C on intestinal epithelium to raise cGMP, promoting chloride/bicarbonate secretion; gut–brain signaling roles have been proposed.',
    evidence: [
      {
        title: 'Guanylin peptides and GC-C signaling (review)',
        year: 2012,
        source: 'PubMed',
        summary: 'Review of guanylin peptide family and GC-C signaling',
        url: 'https://pubmed.ncbi.nlm.nih.gov/22400328/',
      },
    ],
    common_adverse_effects: 'N/A in research catalog context',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '48',
    slug: 'obestatin',
    name: 'Obestatin',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Peptide encoded by the preproghrelin gene; early reports suggested appetite suppression, but findings are inconsistent.',
    mechanism: 'Proposed GPCR interactions remain debated; may counterbalance some ghrelin effects in certain models.',
    evidence: [
      {
        title: 'Obestatin biology: controversies and updates (review)',
        year: 2009,
        source: 'PubMed',
        summary: 'Review of obestatin biology and controversies',
        url: 'https://pubmed.ncbi.nlm.nih.gov/19457485/',
      },
    ],
    common_adverse_effects: 'N/A in research catalog',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '49',
    slug: 'nesfatin-1',
    name: 'Nesfatin-1',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Hypothalamic peptide implicated in satiety, stress responses, and glucose regulation; part of the expanding gut–brain axis map.',
    mechanism: 'Acts centrally to reduce food intake and modulate autonomic output; interacts with CRF and melanocortin pathways in models.',
    evidence: [
      {
        title: 'Nesfatin-1 and energy homeostasis (review)',
        year: 2011,
        source: 'PubMed',
        summary: 'Review of nesfatin-1 in energy homeostasis',
        url: 'https://pubmed.ncbi.nlm.nih.gov/21193022/',
      },
    ],
    common_adverse_effects: 'N/A in research catalog',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '50',
    slug: 'hbd-2',
    name: 'Human Beta-Defensin 2 (HBD-2)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Epithelial antimicrobial peptide induced by infection and inflammation.',
    mechanism: 'Cationic β-sheet peptide that disrupts microbial membranes and signals via chemokine-like pathways to recruit immune cells.',
    evidence: [
      {
        title: 'Human defensins in host defense (review)',
        year: 2006,
        source: 'PubMed',
        summary: 'Review of human defensins in innate immunity',
        url: 'https://pubmed.ncbi.nlm.nih.gov/16424907/',
      },
    ],
    common_adverse_effects: 'N/A in catalog; lab-reagent context',
    contraindications: 'None in research use; inflammatory skin disease requires context in models',
    recommended_dosage: 'Research reagent; not for therapeutic use',
  },
  {
    id: '51',
    slug: 'hbd-3',
    name: 'Human Beta-Defensin 3 (HBD-3)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Potent human defensin with broad Gram-positive/negative activity and immune signaling.',
    mechanism: 'Membrane-disruptive activity; can engage CCR6 and modulate Toll-like receptor pathways.',
    evidence: [
      {
        title: 'Beta-defensins: structure and function (review)',
        year: 2004,
        source: 'PubMed',
        summary: 'Review of beta-defensin structure and antimicrobial function',
        url: 'https://pubmed.ncbi.nlm.nih.gov/15310867/',
      },
    ],
    common_adverse_effects: 'N/A in catalog; reagent context',
    contraindications: 'Research context only',
    recommended_dosage: 'Research reagent; not for therapeutic use',
  },
  {
    id: '52',
    slug: 'hnp-1',
    name: 'Human Neutrophil Peptide-1 (HNP-1)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Granule peptide from neutrophils involved in early antibacterial defense and immune crosstalk.',
    mechanism: 'Forms pores in microbial membranes and modulates cytokines, complement, and chemotaxis.',
    evidence: [
      {
        title: 'Alpha defensins in innate immunity (review)',
        year: 2004,
        source: 'PubMed',
        summary: 'Review of alpha-defensins in innate immune responses',
        url: 'https://pubmed.ncbi.nlm.nih.gov/15546664/',
      },
    ],
    common_adverse_effects: 'N/A; not a therapeutic entry',
    contraindications: 'Research context only',
    recommended_dosage: 'Research reagent only',
  },
  {
    id: '53',
    slug: 'dermcidin',
    name: 'Dermcidin (DCD-1L)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Human sweat-gland peptide secreted onto skin that contributes to surface antimicrobial defense.',
    mechanism: 'Produces broad antimicrobial effects; unusually active in high-salt and variable pH environments typical of sweat.',
    evidence: [
      {
        title: 'Dermcidin: antimicrobial activity in sweat (original report)',
        year: 2002,
        source: 'PubMed',
        summary: 'Original study on dermcidin antimicrobial properties',
        url: 'https://pubmed.ncbi.nlm.nih.gov/12571363/',
      },
    ],
    common_adverse_effects: 'N/A (reagent)',
    contraindications: 'Research context only',
    recommended_dosage: 'Research reagent only',
  },
  {
    id: '54',
    slug: 'histatin-5',
    name: 'Histatin-5',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Salivary peptide important in oral antifungal defense, notably against Candida species.',
    mechanism: 'Binds fungal cell walls and internal targets, leading to ATP leakage and cell death; can bind metals.',
    evidence: [
      {
        title: 'Histatins: antimicrobial peptides of the oral cavity (review)',
        year: 2006,
        source: 'PubMed',
        summary: 'Review of histatin antimicrobial peptides in oral cavity',
        url: 'https://pubmed.ncbi.nlm.nih.gov/17113228/',
      },
    ],
    common_adverse_effects: 'N/A (reagent)',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '55',
    slug: 'pexiganan',
    name: 'Pexiganan (MSI-78)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Synthetic AMP derived from frog magainins, studied topically for diabetic foot infection.',
    mechanism: 'Amphipathic α-helical peptide that disrupts bacterial membranes; broad Gram-positive/negative spectrum in vitro.',
    evidence: [
      {
        title: 'Pexiganan for infected diabetic foot ulcers: clinical data',
        year: 1999,
        source: 'PubMed',
        summary: 'Clinical study of pexiganan in diabetic foot infections',
        url: 'https://pubmed.ncbi.nlm.nih.gov/10428075/',
      },
    ],
    common_adverse_effects: 'Local irritation in studies',
    contraindications: 'Unknown',
    recommended_dosage: 'Topical application in research protocols',
  },
  {
    id: '56',
    slug: 'omiganan',
    name: 'Omiganan (CLS001)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Cationic AMP investigated topically for catheter-site infection prevention and dermatologic conditions.',
    mechanism: 'Membrane permeabilization and modulation of microbial signaling; active against bacteria and some fungi.',
    evidence: [
      {
        title: 'Topical antimicrobial peptides: clinical experience (review)',
        year: 2013,
        source: 'PubMed',
        summary: 'Review of topical antimicrobial peptides in clinical trials',
        url: 'https://pubmed.ncbi.nlm.nih.gov/23394903/',
      },
    ],
    common_adverse_effects: 'Local irritation reported',
    contraindications: 'Unknown',
    recommended_dosage: 'Topical application in research protocols',
  },
  {
    id: '57',
    slug: 'setmelanotide',
    name: 'Setmelanotide (IMCIVREE)',
    regulatory_status: 'FDA-approved',
    summary: 'Peptide agonist for rare genetic obesity due to POMC, PCSK1, or LEPR deficiency, and Bardet–Biedl syndrome.',
    mechanism: 'Selectively activates MC4R in hypothalamic pathways controlling appetite and energy expenditure.',
    evidence: [
      {
        title: 'FDA Approval Summary: Setmelanotide in rare genetic obesity',
        year: 2022,
        source: 'PubMed',
        summary: 'FDA approval summary for setmelanotide',
        url: 'https://pubmed.ncbi.nlm.nih.gov/35403460/',
      },
    ],
    common_adverse_effects: 'Hyperpigmentation, injection-site reactions, nausea (reported)',
    contraindications: 'History of melanoma/atypical nevi warrants caution',
    recommended_dosage: 'Per FDA-approved protocol for genetic obesity',
  },
  {
    id: '58',
    slug: 'teduglutide',
    name: 'Teduglutide (Gattex)',
    regulatory_status: 'FDA-approved',
    summary: 'Intestinal trophic peptide analog approved to reduce parenteral support in adults and children with short bowel syndrome.',
    mechanism: 'Activates GLP-2 receptors to enhance mucosal growth, increase absorption, and improve intestinal barrier function.',
    evidence: [
      {
        title: 'Gattex (teduglutide) prescribing information',
        year: 2019,
        source: 'FDA',
        summary: 'FDA prescribing information for teduglutide',
        url: 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203441s010lbl.pdf',
      },
    ],
    common_adverse_effects: 'Abdominal pain, distension, nausea, potential polyp growth (requires surveillance)',
    contraindications: 'Active GI malignancy (clinical caution)',
    recommended_dosage: 'Per FDA-approved protocol for short bowel syndrome',
  },
  {
    id: '59',
    slug: 'teriparatide',
    name: 'Teriparatide (Forteo)',
    regulatory_status: 'FDA-approved',
    summary: 'Recombinant PTH(1-34) used for osteoporosis in high-risk adults; stimulates bone formation.',
    mechanism: 'Intermittent PTH receptor activation favors osteoblast activity and new bone formation, contrasting with chronic hyperparathyroidism effects.',
    evidence: [
      {
        title: 'Teriparatide efficacy and safety (review)',
        year: 2009,
        source: 'PubMed',
        summary: 'Review of teriparatide clinical efficacy and safety',
        url: 'https://pubmed.ncbi.nlm.nih.gov/19093923/',
      },
    ],
    common_adverse_effects: 'Nausea, dizziness; historical osteosarcoma signal in rats prompted duration limits',
    contraindications: 'Bone malignancy or unexplained elevations in ALP (clinical caution)',
    recommended_dosage: 'Per FDA-approved protocol for osteoporosis',
  },
  {
    id: '60',
    slug: 'abaloparatide',
    name: 'Abaloparatide (Tymlos)',
    regulatory_status: 'FDA-approved',
    summary: 'Analog of parathyroid hormone–related peptide approved for osteoporosis in postmenopausal women at high fracture risk.',
    mechanism: 'Preferentially engages PTH1 receptor conformations that promote anabolic bone formation with potentially different signaling bias vs PTH(1-34).',
    evidence: [
      {
        title: 'Abaloparatide pivotal trial (ACTIVE)',
        year: 2016,
        source: 'PubMed',
        summary: 'ACTIVE trial results for abaloparatide in osteoporosis',
        url: 'https://pubmed.ncbi.nlm.nih.gov/27074024/',
      },
    ],
    common_adverse_effects: 'Dizziness, nausea; orthostatic symptoms reported',
    contraindications: 'Bone malignancy risk considerations similar to PTH-class',
    recommended_dosage: 'Per FDA-approved protocol for osteoporosis',
  },
  {
    id: '61',
    slug: 'linaclotide',
    name: 'Linaclotide (Linzess)',
    regulatory_status: 'FDA-approved',
    summary: 'Intestinal guanylate cyclase-C agonist approved for IBS-C and chronic idiopathic constipation.',
    mechanism: 'Binds GC-C on intestinal epithelium to raise cGMP, increasing chloride/bicarbonate secretion, softening stool, and reducing visceral pain via neuronal cGMP.',
    evidence: [
      {
        title: 'Linaclotide clinical pharmacology and trials (review)',
        year: 2013,
        source: 'PubMed',
        summary: 'Review of linaclotide pharmacology and clinical trials',
        url: 'https://pubmed.ncbi.nlm.nih.gov/23814675/',
      },
    ],
    common_adverse_effects: 'Diarrhea is most common; dehydration risk in pediatrics (boxed warning)',
    contraindications: 'Pediatric patients under label-specified ages (safety warning)',
    recommended_dosage: 'Per FDA-approved protocol for IBS-C/CIC',
  },
  {
    id: '62',
    slug: 'plecanatide',
    name: 'Plecanatide (Trulance)',
    regulatory_status: 'FDA-approved',
    summary: 'Uroguanylin-inspired peptide approved for CIC and IBS-C with pH-tuned activation in the small intestine.',
    mechanism: 'Activates GC-C to increase cGMP and intestinal fluid; designed to be active at near-neutral pH, echoing uroguanylin physiology.',
    evidence: [
      {
        title: 'Plecanatide for CIC/IBS-C: efficacy and safety',
        year: 2019,
        source: 'PubMed',
        summary: 'Study of plecanatide efficacy and safety',
        url: 'https://pubmed.ncbi.nlm.nih.gov/30775835/',
      },
    ],
    common_adverse_effects: 'Diarrhea most common; pediatric warning similar to class',
    contraindications: 'Pediatric age groups per label',
    recommended_dosage: 'Per FDA-approved protocol for CIC/IBS-C',
  },
  {
    id: '63',
    slug: 'foxy-5',
    name: 'Foxy-5',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Peptidic mimetic of Wnt5a signaling studied in oncology for effects on migration and differentiation.',
    mechanism: 'Engages non-canonical Wnt signaling to influence cell polarity, motility, and EMT-related pathways.',
    evidence: [
      {
        title: 'Non-canonical Wnt signaling in cancer (review)',
        year: 2017,
        source: 'PubMed',
        summary: 'Review of non-canonical Wnt signaling in cancer biology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/28483303/',
      },
    ],
    common_adverse_effects: 'Unknown in humans',
    contraindications: 'Unknown',
    recommended_dosage: 'Highly experimental; no established protocols',
  },
  {
    id: '64',
    slug: 'oxytomodulin',
    name: 'Oxytomodulin',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Endogenous gut peptide with dual GLP-1 and glucagon receptor activity explored in appetite and energy expenditure research.',
    mechanism: 'Co-agonism of GLP-1 and glucagon receptors reduces intake and may raise energy expenditure in models.',
    evidence: [
      {
        title: 'Oxytomodulin and energy balance (human studies)',
        year: 2003,
        source: 'PubMed',
        summary: 'Study of oxytomodulin effects on energy balance',
        url: 'https://pubmed.ncbi.nlm.nih.gov/12915404/',
      },
    ],
    common_adverse_effects: 'Nausea in infusion studies',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '65',
    slug: 'retatrutide',
    name: 'Retatrutide (LY3437943)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Investigational triple agonist designed to co-activate GIP, GLP-1, and glucagon receptors for weight and metabolic endpoints.',
    mechanism: 'Balanced co-agonism aims to combine GLP-1 satiety/glycemia control, GIP insulinotropic effects, and glucagon-mediated energy expenditure and lipid mobilization.',
    evidence: [
      {
        title: 'Triple-agonist incretin pharmacology (overview)',
        year: 2023,
        source: 'PubMed',
        summary: 'Overview of triple-agonist incretin approaches',
        url: 'https://pubmed.ncbi.nlm.nih.gov/36610641/',
      },
    ],
    common_adverse_effects: 'Class-typical GI effects in trials (nausea, vomiting); glucagon activity may affect heart rate/metabolism',
    contraindications: 'Personal/family history of medullary thyroid carcinoma/MEN2 (class caution); pancreatitis history (class caution)',
    recommended_dosage: 'Clinical trial protocols; not yet approved',
  },
  {
    id: '66',
    slug: 'anp',
    name: 'Atrial Natriuretic Peptide (ANP)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Endogenous cardiac peptide that promotes natriuresis, vasodilation, and RAAS suppression.',
    mechanism: 'Activates guanylate cyclase-A (NPR-A), elevating cGMP to relax vascular smooth muscle and increase renal sodium excretion.',
    evidence: [
      {
        title: 'Natriuretic peptides and cGMP signaling (review)',
        year: 2012,
        source: 'PubMed',
        summary: 'Review of natriuretic peptides and signaling',
        url: 'https://pubmed.ncbi.nlm.nih.gov/22335713/',
      },
    ],
    common_adverse_effects: 'Hypotension in provocation models',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '67',
    slug: 'nesiritide',
    name: 'Nesiritide (Natrecor)',
    regulatory_status: 'FDA-approved',
    summary: 'Recombinant BNP historically used IV for acute decompensated heart failure; clinical use declined with mixed outcome data.',
    mechanism: 'Activates NPR-A to raise cGMP, causing venodilation/diuresis and reduced cardiac filling pressures.',
    evidence: [
      {
        title: 'Nesiritide in acute HF: evidence summary',
        year: 2011,
        source: 'PubMed',
        summary: 'Evidence summary for nesiritide in heart failure',
        url: 'https://pubmed.ncbi.nlm.nih.gov/21751411/',
      },
    ],
    common_adverse_effects: 'Hypotension, renal function shifts',
    contraindications: 'Symptomatic hypotension',
    recommended_dosage: 'Per FDA-approved protocol for acute heart failure',
  },
  {
    id: '68',
    slug: 'vosoritide',
    name: 'Vosoritide (BMN 111)',
    regulatory_status: 'FDA-approved',
    summary: 'Engineered CNP analog for children with achondroplasia to promote endochondral bone growth.',
    mechanism: 'Stimulates NPR-B/cGMP signaling in growth plate chondrocytes, counterbalancing overactive FGFR3 signaling in achondroplasia.',
    evidence: [
      {
        title: 'Vosoritide trial in achondroplasia',
        year: 2021,
        source: 'PubMed',
        summary: 'Clinical trial results for vosoritide in achondroplasia',
        url: 'https://pubmed.ncbi.nlm.nih.gov/34758553/',
      },
    ],
    common_adverse_effects: 'Injection-site reactions, hypotension',
    contraindications: 'Unknown',
    recommended_dosage: 'Per FDA-approved protocol for achondroplasia',
  },
  {
    id: '69',
    slug: 'calcitonin-salmon',
    name: 'Calcitonin (salmon)',
    regulatory_status: 'FDA-approved',
    summary: 'Peptide for Paget disease and (historically) osteoporosis; modern use is limited.',
    mechanism: 'Activates calcitonin receptors to decrease osteoclast activity and reduce bone resorption; also analgesic effects in some pain syndromes.',
    evidence: [
      {
        title: 'Calcitonin clinical use and limitations (review)',
        year: 2013,
        source: 'PubMed',
        summary: 'Review of calcitonin clinical applications',
        url: 'https://pubmed.ncbi.nlm.nih.gov/23877076/',
      },
    ],
    common_adverse_effects: 'Nausea, flushing, rhinitis (nasal)',
    contraindications: 'Unknown',
    recommended_dosage: 'Per FDA-approved protocol for Paget disease',
  },
  {
    id: '70',
    slug: 'cgrp',
    name: 'Calcitonin Gene-Related Peptide (CGRP)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Potent vasodilator implicated in migraine pathophysiology; used in human provocation models.',
    mechanism: 'Activates CGRP receptors on vascular and neural targets, increasing cAMP and promoting vasodilation and nociceptive signaling.',
    evidence: [
      {
        title: 'CGRP in migraine (review)',
        year: 2019,
        source: 'PubMed',
        summary: 'Review of CGRP role in migraine pathophysiology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/31177888/',
      },
    ],
    common_adverse_effects: 'Headache in provocation studies',
    contraindications: 'Research context only',
    recommended_dosage: 'Research provocation protocols only',
  },
  {
    id: '71',
    slug: 'cck-8',
    name: 'Cholecystokinin Octapeptide (CCK-8)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Classic satiety peptide used to study gallbladder contraction, pancreatic secretion, and appetite regulation.',
    mechanism: 'Activates CCK-A/B receptors, stimulating gallbladder and pancreatic enzyme secretion and signaling satiety via vagal/CNS pathways.',
    evidence: [
      {
        title: 'CCK physiology and appetite (review)',
        year: 2011,
        source: 'PubMed',
        summary: 'Review of CCK in appetite and digestive physiology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/22099672/',
      },
    ],
    common_adverse_effects: 'Abdominal cramping in provocation studies',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '72',
    slug: 'grp',
    name: 'Gastrin-Releasing Peptide (GRP)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Neuropeptide that stimulates gastrin release and modulates satiety and stress circuits.',
    mechanism: 'Binds GRP receptors to influence gastric acid secretion, pancreatic function, and CNS behaviors.',
    evidence: [
      {
        title: 'GRP/GRPR in physiology and cancer (review)',
        year: 2011,
        source: 'PubMed',
        summary: 'Review of GRP receptor biology and applications',
        url: 'https://pubmed.ncbi.nlm.nih.gov/22142605/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '73',
    slug: 'npy',
    name: 'Neuropeptide Y (NPY)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Abundant CNS peptide regulating appetite, stress resilience, vasomotion, and pain modulation.',
    mechanism: 'Acts at Y1/Y2/Y5 receptors to influence feeding behavior, anxiety circuits, and sympathetic activity.',
    evidence: [
      {
        title: 'Neuropeptide Y in emotion and energy balance (review)',
        year: 2015,
        source: 'PubMed',
        summary: 'Review of NPY in emotion regulation and energy balance',
        url: 'https://pubmed.ncbi.nlm.nih.gov/25870535/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '74',
    slug: 'cart-peptide',
    name: 'CART Peptide',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Hypothalamic peptide implicated in satiety, reward, and stress responses.',
    mechanism: 'Modulates mesolimbic reward and hypothalamic feeding circuits; receptor pharmacology is still being clarified.',
    evidence: [
      {
        title: 'CART peptides in appetite and reward (review)',
        year: 2012,
        source: 'PubMed',
        summary: 'Review of CART peptides in appetite and reward pathways',
        url: 'https://pubmed.ncbi.nlm.nih.gov/22421562/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '75',
    slug: 'glucagon',
    name: 'Glucagon (research entry)',
    regulatory_status: 'FDA-approved (therapeutic forms exist for severe hypoglycemia)',
    summary: 'Endogenous counter-regulatory hormone that raises blood glucose and influences lipid metabolism; pivotal in energy homeostasis.',
    mechanism: 'Activates hepatic glucagon receptors to stimulate glycogenolysis, gluconeogenesis, and lipolysis; increases energy expenditure.',
    evidence: [
      {
        title: 'Glucagon physiology and therapeutics (review)',
        year: 2018,
        source: 'PubMed',
        summary: 'Review of glucagon physiology and therapeutic applications',
        url: 'https://pubmed.ncbi.nlm.nih.gov/29500308/',
      },
    ],
    common_adverse_effects: 'Nausea in provocation/therapy settings',
    contraindications: 'Unknown',
    recommended_dosage: 'Emergency use for severe hypoglycemia per FDA protocols',
  },
  {
    id: '76',
    slug: 'dulaglutide',
    name: 'Dulaglutide (Trulicity)',
    regulatory_status: 'FDA-approved',
    summary: 'Long-acting GLP-1 RA for type 2 diabetes with cardiovascular outcome data.',
    mechanism: 'Sustained GLP-1 receptor activation improves glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite.',
    evidence: [
      {
        title: 'Dulaglutide clinical outcomes (REWIND)',
        year: 2019,
        source: 'PubMed',
        summary: 'REWIND trial cardiovascular outcomes for dulaglutide',
        url: 'https://pubmed.ncbi.nlm.nih.gov/31189511/',
      },
    ],
    common_adverse_effects: 'Nausea, diarrhea; gallbladder disease risk',
    contraindications: 'MTC/MEN2 history; pancreatitis history (class caution)',
    recommended_dosage: 'Per FDA-approved protocol for type 2 diabetes',
  },
  {
    id: '77',
    slug: 'lixisenatide',
    name: 'Lixisenatide (Adlyxin)',
    regulatory_status: 'FDA-approved',
    summary: 'Once-daily GLP-1 RA for type 2 diabetes; often discussed in fixed-ratio combos with basal insulin.',
    mechanism: 'GLP-1 receptor activation to enhance glucose-dependent insulin secretion and delay gastric emptying.',
    evidence: [
      {
        title: 'Lixisenatide efficacy and safety (review)',
        year: 2015,
        source: 'PubMed',
        summary: 'Review of lixisenatide clinical efficacy and safety',
        url: 'https://pubmed.ncbi.nlm.nih.gov/26453131/',
      },
    ],
    common_adverse_effects: 'Nausea, vomiting',
    contraindications: 'MTC/MEN2 history; pancreatitis history (class caution)',
    recommended_dosage: 'Per FDA-approved protocol for type 2 diabetes',
  },
  {
    id: '78',
    slug: 'ghrelin',
    name: 'Ghrelin (acyl-ghrelin)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Endogenous hunger hormone that also modulates GH release, glucose homeostasis, and reward pathways.',
    mechanism: 'Activates GHSR-1a; requires octanoylation for receptor binding; increases appetite, GH pulses, and GI motility.',
    evidence: [
      {
        title: 'Ghrelin biology and clinical implications (review)',
        year: 2018,
        source: 'PubMed',
        summary: 'Review of ghrelin biology and clinical implications',
        url: 'https://pubmed.ncbi.nlm.nih.gov/29469313/',
      },
    ],
    common_adverse_effects: 'Hunger in provocation studies',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '79',
    slug: 'kisspeptin-54',
    name: 'Kisspeptin-54',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Longer kisspeptin fragment used to stimulate GnRH/LH axis in human physiology studies.',
    mechanism: 'Activates KISS1R on GnRH neurons, eliciting LH/FSH release; longer fragment offers different kinetics vs KP-10.',
    evidence: [
      {
        title: 'Human kisspeptin infusion studies',
        year: 2007,
        source: 'PubMed',
        summary: 'Study of kisspeptin infusion effects on reproductive hormones',
        url: 'https://pubmed.ncbi.nlm.nih.gov/17997633/',
      },
    ],
    common_adverse_effects: 'Flushing, transient nausea',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '80',
    slug: 'orexin-a',
    name: 'Orexin-A (Hypocretin-1)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Endogenous hypothalamic peptide essential for wakefulness stability, reward, and energy balance; loss of orexin neurons causes narcolepsy with cataplexy.',
    mechanism: 'Binds orexin receptors OX1R and OX2R to excite monoaminergic/cholinergic arousal networks and modulate reward/autonomic output.',
    evidence: [
      {
        title: 'Orexin/hypocretin system and arousal (review)',
        year: 2011,
        source: 'PubMed',
        summary: 'Review of orexin system in arousal and sleep regulation',
        url: 'https://pubmed.ncbi.nlm.nih.gov/21501697/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '81',
    slug: 'orexin-b',
    name: 'Orexin-B (Hypocretin-2)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Partner peptide to orexin-A with overlapping but distinct receptor preferences and physiological roles.',
    mechanism: 'Preferentially activates OX2R (also binds OX1R), reinforcing wake drive, REM suppression, and autonomic/metabolic outputs.',
    evidence: [
      {
        title: 'Orexin receptor biology (overview)',
        year: 2010,
        source: 'PubMed',
        summary: 'Overview of orexin receptor pharmacology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/20097222/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '82',
    slug: 'beta-endorphin',
    name: 'β-Endorphin',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'POMC-derived opioid peptide involved in analgesia, stress response, and reward; acts primarily at μ-opioid receptors.',
    mechanism: 'Activates MOR (μ-opioid receptors) to inhibit nociceptive transmission and modulate dopaminergic reward pathways.',
    evidence: [
      {
        title: 'Endogenous opioids: physiology and behavior (review)',
        year: 2011,
        source: 'PubMed',
        summary: 'Review of endogenous opioid systems',
        url: 'https://pubmed.ncbi.nlm.nih.gov/21986472/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '83',
    slug: 'met-enkephalin',
    name: 'Met-Enkephalin',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Pentapeptide opioid transmitter enriched in CNS circuits for pain modulation and affect.',
    mechanism: 'Preferentially activates δ-opioid receptors (also μ), inhibiting neurotransmitter release and nociceptive signaling.',
    evidence: [
      {
        title: 'Enkephalinergic modulation of pain (review)',
        year: 2011,
        source: 'PubMed',
        summary: 'Review of enkephalin systems in pain modulation',
        url: 'https://pubmed.ncbi.nlm.nih.gov/21576136/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '84',
    slug: 'dynorphin-a',
    name: 'Dynorphin A (1-17)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Kappa-preferring opioid peptide implicated in stress dysphoria, analgesia, and negative affect.',
    mechanism: 'Activates κ-opioid receptors (KOR), producing analgesia but also dysphoria/aversive states via mesolimbic modulation.',
    evidence: [
      {
        title: 'Dynorphin–KOR in stress and addiction (review)',
        year: 2015,
        source: 'PubMed',
        summary: 'Review of dynorphin-KOR system in stress and addiction',
        url: 'https://pubmed.ncbi.nlm.nih.gov/25770799/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '85',
    slug: 'nociceptin',
    name: 'Nociceptin/Orphanin FQ (N/OFQ)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Opioid-like peptide with distinct receptor (NOP) that modulates pain, stress, and reward with context-dependent effects.',
    mechanism: 'Binds NOP receptor (distinct from μ/δ/κ) to regulate neurotransmission; can be anti- or pro-nociceptive depending on site.',
    evidence: [
      {
        title: 'Nociceptin/OFQ system overview',
        year: 2011,
        source: 'PubMed',
        summary: 'Overview of nociceptin/OFQ system biology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/21971049/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '86',
    slug: 'neurotensin',
    name: 'Neurotensin',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Triple-domain peptide involved in pain modulation, thermoregulation, dopaminergic signaling, and gut motility.',
    mechanism: 'Acts on NTSR1/NTSR2 GPCRs; modulates dopamine pathways and spinal nociception; peripheral effects include GI motility.',
    evidence: [
      {
        title: 'Neurotensin biology and receptors (review)',
        year: 2010,
        source: 'PubMed',
        summary: 'Review of neurotensin receptor biology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/20869990/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '87',
    slug: 'nps',
    name: 'Neuropeptide S (NPS)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Brainstem-origin peptide that produces wakefulness and anxiolysis, an unusual combination in arousal pharmacology.',
    mechanism: 'Activates NPSR1 (GPCR) to promote arousal while reducing anxiety-like behavior in rodent models.',
    evidence: [
      {
        title: 'Neuropeptide S and arousal/anxiety (review)',
        year: 2010,
        source: 'PubMed',
        summary: 'Review of NPS in arousal and anxiety regulation',
        url: 'https://pubmed.ncbi.nlm.nih.gov/20122999/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '88',
    slug: 'bombesin',
    name: 'Bombesin',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Frog-derived peptide that inspired discovery of mammalian GRP; used as a tool for GRPR imaging/targeting.',
    mechanism: 'Agonizes GRP receptors influencing gastric secretion, satiety, and CNS behaviors; radiolabeled analogs aid tumor imaging.',
    evidence: [
      {
        title: 'Bombesin/GRP systems and cancer imaging (review)',
        year: 2012,
        source: 'PubMed',
        summary: 'Review of bombesin receptor systems in imaging',
        url: 'https://pubmed.ncbi.nlm.nih.gov/22313643/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '89',
    slug: 'secretin',
    name: 'Secretin (native)',
    regulatory_status: 'Research-only/Unapproved (diagnostic formulations exist)',
    summary: 'Duodenal peptide that stimulates pancreatic bicarbonate secretion and modulates gastric acid; classic physiology peptide.',
    mechanism: 'Activates secretin receptors on pancreatic ductal cells to raise cAMP and bicarbonate secretion; influences gastric/duodenal motility.',
    evidence: [
      {
        title: 'Secretin physiology and clinical uses (review)',
        year: 2006,
        source: 'PubMed',
        summary: 'Review of secretin physiology and diagnostic uses',
        url: 'https://pubmed.ncbi.nlm.nih.gov/16431821/',
      },
    ],
    common_adverse_effects: 'Research context; diagnostic use well-tolerated',
    contraindications: 'Research/diagnostic context',
    recommended_dosage: 'Diagnostic protocols per clinical use',
  },
  {
    id: '90',
    slug: 'gastrin',
    name: 'Gastrin (native)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Antral peptide that stimulates gastric acid secretion and mucosal growth via CCK-B receptors.',
    mechanism: 'Binds CCK-B receptors on parietal cells and ECL cells to enhance acid output and histamine release.',
    evidence: [
      {
        title: 'Gastrin biology and pathology (review)',
        year: 2005,
        source: 'PubMed',
        summary: 'Review of gastrin in digestive physiology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/16027035/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '91',
    slug: 'gip',
    name: 'GIP (Glucose-dependent Insulinotropic Polypeptide)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Duodenal/jejunal K-cell peptide that enhances glucose-stimulated insulin secretion; co-targeted in modern dual agonists.',
    mechanism: 'Binds GIP receptors on β-cells to potentiate insulin release; has adipose and CNS effects in models.',
    evidence: [
      {
        title: 'GIP physiology and therapeutic implications (review)',
        year: 2019,
        source: 'PubMed',
        summary: 'Review of GIP in metabolic physiology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/30779629/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '92',
    slug: 'glp-2',
    name: 'GLP-2 (Glucagon-like Peptide-2)',
    regulatory_status: 'Research-only/Unapproved (analog approved: teduglutide)',
    summary: 'Proglucagon-derived peptide that promotes intestinal growth and barrier function; therapeutic impact realized via stable analogs.',
    mechanism: 'Activates GLP-2R on enteric neurons and epithelium to enhance mucosal growth, absorption, and barrier integrity.',
    evidence: [
      {
        title: 'GLP-2 biology and therapy (review)',
        year: 2017,
        source: 'PubMed',
        summary: 'Review of GLP-2 biology and therapeutic applications',
        url: 'https://pubmed.ncbi.nlm.nih.gov/28178576/',
      },
    ],
    common_adverse_effects: 'Research context; analog (teduglutide) has known profile',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only; see teduglutide for approved analog',
  },
  {
    id: '93',
    slug: 'leptin',
    name: 'Leptin (native)',
    regulatory_status: 'Research-only/Unapproved (for general obesity); analog approved for rare deficiency',
    summary: 'Adipocyte-derived hormone that signals energy stores to the hypothalamus to regulate appetite and metabolism.',
    mechanism: 'Binds leptin receptors (Ob-Rb) in hypothalamus to reduce food intake and increase energy expenditure; widespread peripheral actions.',
    evidence: [
      {
        title: 'Leptin and the regulation of body weight (review)',
        year: 2001,
        source: 'PubMed',
        summary: 'Foundational review of leptin in energy balance',
        url: 'https://pubmed.ncbi.nlm.nih.gov/11557872/',
      },
    ],
    common_adverse_effects: 'Research context; replacement therapy in deficiency generally tolerated',
    contraindications: 'Research context only',
    recommended_dosage: 'See metreleptin for approved analog',
  },
  {
    id: '94',
    slug: 'metreleptin',
    name: 'Metreleptin (Myalept)',
    regulatory_status: 'FDA-approved',
    summary: 'Recombinant leptin analog approved for generalized lipodystrophy to correct severe leptin deficiency and metabolic complications.',
    mechanism: 'Restores leptin signaling to improve satiety, insulin sensitivity, hypertriglyceridemia, and endocrine abnormalities in leptin-deficient states.',
    evidence: [
      {
        title: 'Metreleptin therapy in lipodystrophy (review)',
        year: 2017,
        source: 'PubMed',
        summary: 'Review of metreleptin therapy in lipodystrophy',
        url: 'https://pubmed.ncbi.nlm.nih.gov/28613180/',
      },
    ],
    common_adverse_effects: 'Headache, hypoglycemia (with insulin), injection-site reactions; anti-drug antibodies possible',
    contraindications: 'Hypersensitivity; caution with immunogenicity and lymphoma risk discussion in label',
    recommended_dosage: 'Per FDA-approved protocol for lipodystrophy',
  },
  {
    id: '95',
    slug: 'somatropin',
    name: 'Somatropin (recombinant human Growth Hormone)',
    regulatory_status: 'FDA-approved',
    summary: 'Recombinant form of human growth hormone used for clearly defined pediatric and adult growth hormone deficiency syndromes.',
    mechanism: 'Binds GH receptors to activate JAK2/STAT signaling, increasing IGF-1 production and promoting linear growth, protein synthesis, and lipolysis.',
    evidence: [
      {
        title: 'Clinical practice guideline: GH therapy in children and adolescents',
        year: 2016,
        source: 'Endocrine Society (PubMed)',
        summary: 'Clinical practice guidelines for GH therapy',
        url: 'https://pubmed.ncbi.nlm.nih.gov/26522654/',
      },
      {
        title: 'Somatropin labeling overview',
        year: 2025,
        source: 'FDA',
        summary: 'FDA labeling information for somatropin',
        url: 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm',
      },
    ],
    common_adverse_effects: 'Edema, Arthralgia, Myalgia, Carpal tunnel symptoms, Insulin resistance/glucose effects, Benign intracranial hypertension (rare)',
    contraindications: 'Active malignancy, Acute critical illness after surgery/trauma, Severe obesity or respiratory impairment in Prader–Willi',
    recommended_dosage: 'Per FDA-approved protocols for various indications (GH deficiency, Turner syndrome, etc.)',
  },
  {
    id: '96',
    slug: 'relaxin-3',
    name: 'Relaxin-3 (RLN3)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Brain-predominant relaxin-family peptide implicated in arousal, stress, appetite, and cognitive circuits.',
    mechanism: 'Binds RXFP3 receptors (Gi/o) widely expressed in limbic/brainstem regions, modulating GABA/glutamate release and stress/autonomic outputs.',
    evidence: [
      {
        title: 'Relaxin-3/RXFP3 system in the brain (review)',
        year: 2014,
        source: 'PubMed',
        summary: 'Review of relaxin-3 neurobiology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/24852141/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '97',
    slug: 'urocortin-3',
    name: 'Urocortin-3 (UCN3)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Selective CRF2 agonist studied for stress recovery and glucose–insulin interplay.',
    mechanism: 'Preferentially activates CRF2 receptors to modulate stress-axis dampening, autonomic tone, and β-cell function in models.',
    evidence: [
      {
        title: 'Urocortins and CRF2 signaling (overview)',
        year: 2012,
        source: 'PubMed',
        summary: 'Overview of urocortin family and CRF2 biology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/23030884/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '98',
    slug: 'neuromedin-u',
    name: 'Neuromedin U (NMU)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Hypothalamic–gut peptide influencing energy balance, nociception, and stress responses.',
    mechanism: 'Activates NMUR1 (peripheral) and NMUR2 (CNS) to reduce food intake, modulate pain, and affect HPA axis tone in models.',
    evidence: [
      {
        title: 'Neuromedin U physiology (review)',
        year: 2006,
        source: 'PubMed',
        summary: 'Review of neuromedin U physiological functions',
        url: 'https://pubmed.ncbi.nlm.nih.gov/16923351/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '99',
    slug: 'neuropeptide-w',
    name: 'Neuropeptide W (NPW)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Peptide ligand for GPR7/8 (NPBWR1/2) involved in feeding, stress, and nociception.',
    mechanism: 'Activates NPBWR1/2 to influence hypothalamic feeding and HPA output; spinal roles in pain processing.',
    evidence: [
      {
        title: 'Neuropeptide W/B signaling (review)',
        year: 2006,
        source: 'PubMed',
        summary: 'Review of neuropeptide W/B receptor systems',
        url: 'https://pubmed.ncbi.nlm.nih.gov/17011598/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '100',
    slug: 'pyy-1-36',
    name: 'Peptide YY (1-36)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Full-length PYY precursor to the anorexigenic PYY(3-36); broader Y-receptor activity including Y1/Y2.',
    mechanism: 'Acts on multiple NPY receptors; DPP-IV cleaves to PYY(3-36) which preferentially activates Y2 for satiety signaling.',
    evidence: [
      {
        title: 'PYY processing and satiety signaling',
        year: 2005,
        source: 'PubMed',
        summary: 'Study of PYY processing and satiety mechanisms',
        url: 'https://pubmed.ncbi.nlm.nih.gov/15620462/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '101',
    slug: 'glp-1-native',
    name: 'GLP-1 (native)',
    regulatory_status: 'Research-only/Unapproved (analogs approved)',
    summary: 'Gut incretin that boosts glucose-dependent insulin secretion and satiety; native form is rapidly degraded by DPP-IV.',
    mechanism: 'Activates GLP-1 receptors on β-cells, brainstem, and vagal afferents; slows gastric emptying and reduces appetite.',
    evidence: [
      {
        title: 'GLP-1 physiology and therapeutics (review)',
        year: 2014,
        source: 'PubMed',
        summary: 'Review of GLP-1 physiology and drug development',
        url: 'https://pubmed.ncbi.nlm.nih.gov/25457367/',
      },
    ],
    common_adverse_effects: 'Research context; analogs have known profiles',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only; see GLP-1 analogs for therapeutics',
  },
  {
    id: '102',
    slug: 'des-acyl-ghrelin',
    name: 'Des-acyl Ghrelin',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Major circulating ghrelin form lacking the octanoyl group; does not bind GHSR-1a yet exhibits independent metabolic/cardiac actions in models.',
    mechanism: 'Acts via non-GHSR-1a targets (still under study) to influence insulin sensitivity, cardioprotection, and muscle metabolism.',
    evidence: [
      {
        title: 'Des-acyl ghrelin: actions beyond GHSR-1a',
        year: 2013,
        source: 'PubMed',
        summary: 'Study of des-acyl ghrelin independent actions',
        url: 'https://pubmed.ncbi.nlm.nih.gov/24363473/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '103',
    slug: 'protegrin-1',
    name: 'Protegrin-1 (PG-1)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'β-hairpin AMP with potent Gram-negative activity; template for peptidomimetic antibiotics.',
    mechanism: 'Forms β-sheet pores in bacterial membranes; resists some proteases due to disulfide-stabilized hairpin.',
    evidence: [
      {
        title: 'Protegrin structure and antimicrobial action',
        year: 1998,
        source: 'PubMed',
        summary: 'Structural study of protegrin antimicrobial mechanisms',
        url: 'https://pubmed.ncbi.nlm.nih.gov/9435218/',
      },
    ],
    common_adverse_effects: 'Research context; potential hemolysis in therapeutic concentrations',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '104',
    slug: 'temporin-l',
    name: 'Temporin L',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Short amphipathic α-helical AMP with broad activity and notable membrane selectivity studies.',
    mechanism: 'Inserts into lipid bilayers causing permeabilization; activity modulated by membrane composition and peptide aggregation state.',
    evidence: [
      {
        title: 'Temporin L biophysics and selectivity',
        year: 2014,
        source: 'PubMed',
        summary: 'Study of temporin L membrane selectivity',
        url: 'https://pubmed.ncbi.nlm.nih.gov/25296312/',
      },
    ],
    common_adverse_effects: 'Research context; not for therapeutic use',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '105',
    slug: 'magainin-2',
    name: 'Magainin-2',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Classic α-helical AMP that helped launch the field of peptide antibiotics and inspired pexiganan design.',
    mechanism: 'Forms toroidal pores in microbial membranes; activity depends on charge, helix, and membrane composition.',
    evidence: [
      {
        title: 'Magainins: from discovery to design (review)',
        year: 2001,
        source: 'PubMed',
        summary: 'Review of magainin discovery and peptide antibiotic design',
        url: 'https://pubmed.ncbi.nlm.nih.gov/11343853/',
      },
    ],
    common_adverse_effects: 'Research context; inspired pexiganan development',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '106',
    slug: 'hnp-3',
    name: 'Human Alpha-Defensin 3 (HNP-3)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Granule peptide from neutrophils with strong antimicrobial activity and immunomodulation; complements HNP-1.',
    mechanism: 'Cationic β-sheet peptide that disrupts microbial membranes and influences cytokine networks.',
    evidence: [
      {
        title: 'Human α-defensins in host defense (review)',
        year: 2006,
        source: 'PubMed',
        summary: 'Review of alpha-defensins in innate immunity',
        url: 'https://pubmed.ncbi.nlm.nih.gov/16424907/',
      },
    ],
    common_adverse_effects: 'Research context; not for therapeutic use',
    contraindications: 'Research context only',
    recommended_dosage: 'Research reagent only',
  },
  {
    id: '107',
    slug: 'adrenomedullin-2',
    name: 'Adrenomedullin-2 (Intermedin)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Adrenomedullin-related peptide with overlapping cardiovascular and fluid-balance biology.',
    mechanism: 'Signals via CLR/RAMP receptor complexes to increase cAMP and NO, affecting tone and endothelial protection.',
    evidence: [
      {
        title: 'Intermedin/Adrenomedullin-2: physiology (review)',
        year: 2009,
        source: 'PubMed',
        summary: 'Review of intermedin cardiovascular physiology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/19218162/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '108',
    slug: 'endothelin-3',
    name: 'Endothelin-3 (ET-3)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Member of the endothelin family with developmental roles (neural crest/enteric nervous system) and vascular signaling.',
    mechanism: 'Binds ETB (and ETA) receptors; key in melanocyte/enteric neuron development and endothelial function.',
    evidence: [
      {
        title: 'Endothelin-3 and development (review)',
        year: 2001,
        source: 'PubMed',
        summary: 'Review of endothelin-3 in developmental biology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/11181958/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '109',
    slug: 'neurokinin-b',
    name: 'Neurokinin B (NKB)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Hypothalamic peptide essential for reproductive axis pulsatility; TAC3/TACR3 mutations cause hypogonadotropic hypogonadism.',
    mechanism: 'Activates NK3 receptors on KNDy neurons that coordinate GnRH pulse generation with kisspeptin and dynorphin.',
    evidence: [
      {
        title: 'KNDy neurons and reproductive pulses (review)',
        year: 2014,
        source: 'PubMed',
        summary: 'Review of KNDy neuron system in reproductive endocrinology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/25081466/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '110',
    slug: 'motilin',
    name: 'Motilin',
    regulatory_status: 'Research-only/Unapproved (motilin agonists exist)',
    summary: 'Twenty-two–amino-acid peptide secreted from small-intestinal M cells that triggers fasting-state gut contractions.',
    mechanism: 'Binds motilin receptors on smooth muscle and enteric nerves to initiate migrating motor complexes.',
    evidence: [
      {
        title: 'Motilin physiology and clinical relevance',
        year: 2005,
        source: 'PubMed',
        summary: 'Review of motilin physiology and GI motility',
        url: 'https://pubmed.ncbi.nlm.nih.gov/15870184/',
      },
    ],
    common_adverse_effects: 'Research context; agonists have known profiles',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '111',
    slug: 'galp',
    name: 'Galanin-Like Peptide (GALP)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Hypothalamic peptide related to galanin, integrating energy balance and reproductive signaling.',
    mechanism: 'Acts through galanin receptors and specific GALP receptors to influence appetite and GnRH release.',
    evidence: [
      {
        title: 'GALP: energy and reproductive integration',
        year: 2004,
        source: 'PubMed',
        summary: 'Study of GALP role in energy and reproduction',
        url: 'https://pubmed.ncbi.nlm.nih.gov/15294876/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '112',
    slug: 'enteroglucagon',
    name: 'Enteroglucagon',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Composite term for intestinal proglucagon products (GLP-1, GLP-2, oxyntomodulin) influencing gut growth and secretion.',
    mechanism: 'Activates GLP-1, GLP-2, and glucagon receptors in various tissues to coordinate nutrient absorption and mucosal maintenance.',
    evidence: [
      {
        title: 'Proglucagon processing and enteroglucagon concept',
        year: 2007,
        source: 'PubMed',
        summary: 'Review of proglucagon processing in intestine',
        url: 'https://pubmed.ncbi.nlm.nih.gov/17352642/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '113',
    slug: 'vip-analogs',
    name: 'VIP Analogs (Synthetic VIP fragments)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Modified VIP fragments explored to improve stability and receptor selectivity for inflammatory airway disease models.',
    mechanism: 'Partial agonists at VPAC1/2 receptors reducing cytokine release and promoting bronchodilation.',
    evidence: [
      {
        title: 'VIP analogs in airway inflammation',
        year: 2009,
        source: 'PubMed',
        summary: 'Study of VIP analogs in pulmonary inflammation',
        url: 'https://pubmed.ncbi.nlm.nih.gov/19571586/',
      },
    ],
    common_adverse_effects: 'Research context; stability-improved variants',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '114',
    slug: 'collagen-peptide',
    name: 'Collagen Peptide (Hydrolyzed Collagen)',
    regulatory_status: 'Research-only/Unapproved (nutritional category)',
    summary: 'Short glycine-proline-hydroxyproline–rich peptides studied for cartilage and skin ECM metabolism.',
    mechanism: 'Provide di- and tri-peptides that may stimulate fibroblast collagen synthesis or serve as signaling molecules through GPRs.',
    evidence: [
      {
        title: 'Bioactive collagen peptides and skin elasticity',
        year: 2013,
        source: 'PubMed',
        summary: 'Study of collagen peptides in skin health',
        url: 'https://pubmed.ncbi.nlm.nih.gov/23949208/',
      },
    ],
    common_adverse_effects: 'Generally well tolerated as nutritional supplement',
    contraindications: 'None specific in research contexts',
    recommended_dosage: 'Nutritional supplement dosing; 2.5-15g daily in studies',
  },
  {
    id: '115',
    slug: 'osteostatin',
    name: 'Osteostatin (PTHrP 107-111)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'C-terminal pentapeptide fragment of parathyroid hormone–related protein studied for bone anabolism modulation.',
    mechanism: 'Influences osteoblast proliferation and differentiation via PKC and cAMP pathways distinct from full-length PTH/PTHrP signaling.',
    evidence: [
      {
        title: 'Osteostatin and bone remodeling',
        year: 2009,
        source: 'PubMed',
        summary: 'Study of osteostatin in bone biology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/19186642/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '116',
    slug: 'bnp',
    name: 'BNP (Brain Natriuretic Peptide)',
    regulatory_status: 'FDA-approved (diagnostic biomarker)',
    summary: 'Cardiac-derived peptide used as biomarker for heart failure diagnosis and prognosis.',
    mechanism: 'Secreted from ventricles in response to stretch; activates NPR-A to induce natriuresis, vasodilation, and RAAS inhibition.',
    evidence: [
      {
        title: 'BNP/NT-proBNP in heart failure diagnosis',
        year: 2020,
        source: 'PubMed',
        summary: 'Review of BNP as heart failure biomarker',
        url: 'https://pubmed.ncbi.nlm.nih.gov/32798549/',
      },
    ],
    common_adverse_effects: 'Diagnostic use; not administered as therapy',
    contraindications: 'Diagnostic context',
    recommended_dosage: 'Biomarker measurement; not dosed',
  },
  {
    id: '117',
    slug: 'beta-cgrp',
    name: 'β-CGRP',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Peripheral isoform of CGRP with roles in vascular regulation and nociception.',
    mechanism: 'Binds CGRP receptors to cause vasodilation and transmit pain; distributed more in peripheral nervous system than α-CGRP.',
    evidence: [
      {
        title: 'CGRP isoforms and vascular function',
        year: 2015,
        source: 'PubMed',
        summary: 'Study of CGRP isoforms in vascular biology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/25949746/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '118',
    slug: 'endomorphin-1',
    name: 'Endomorphin-1',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Brain-specific μ-opioid receptor agonist peptide with high selectivity over other opioid receptors.',
    mechanism: 'Binds μ-opioid receptor (MOR) producing potent analgesia in animal models with less respiratory depression in some contexts.',
    evidence: [
      {
        title: 'Endomorphins: structure and pharmacology',
        year: 2008,
        source: 'PubMed',
        summary: 'Review of endomorphin pharmacology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/18528535/',
      },
    ],
    common_adverse_effects: 'Research context; rapid degradation limits use',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '119',
    slug: 'npy-13-36',
    name: 'NPY Fragment (13-36)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Truncated NPY fragment that selectively activates Y2 receptors to inhibit neurotransmitter release.',
    mechanism: 'Acts as Y2-preferring agonist; used experimentally to map presynaptic inhibition in sympathetic and central circuits.',
    evidence: [
      {
        title: 'NPY receptor subtype pharmacology',
        year: 2005,
        source: 'PubMed',
        summary: 'Study of NPY receptor subtypes',
        url: 'https://pubmed.ncbi.nlm.nih.gov/16274948/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '120',
    slug: 'bradykinin-1-7',
    name: 'Bradykinin Fragment 1-7',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Stable bradykinin fragment with independent cardiovascular and renal signaling actions.',
    mechanism: 'Acts partly via Mas and AT2 receptors to produce vasodilation and anti-fibrotic effects distinct from full BK.',
    evidence: [
      {
        title: 'Bradykinin fragments and Mas receptor signaling',
        year: 2013,
        source: 'PubMed',
        summary: 'Study of bradykinin fragment signaling',
        url: 'https://pubmed.ncbi.nlm.nih.gov/23390390/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '121',
    slug: 'elabela',
    name: 'Elabela (Apela)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Recently discovered endogenous ligand for the apelin receptor with developmental and cardiovascular functions.',
    mechanism: 'Binds APJ receptor to promote angiogenesis, vasodilation, and embryonic cardiovascular development.',
    evidence: [
      {
        title: 'Elabela/APJ signaling and cardiovascular development',
        year: 2016,
        source: 'PubMed',
        summary: 'Discovery of elabela and APJ receptor signaling',
        url: 'https://pubmed.ncbi.nlm.nih.gov/26802255/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '122',
    slug: 'prrp',
    name: 'Prolactin-Releasing Peptide (PrRP)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Neuropeptide that stimulates prolactin release and regulates feeding and stress pathways.',
    mechanism: 'Binds GPR10 and NPFF2 receptors; influences HPA axis and energy homeostasis.',
    evidence: [
      {
        title: 'Prolactin-releasing peptide: functions and receptors',
        year: 2005,
        source: 'PubMed',
        summary: 'Review of PrRP receptor biology and functions',
        url: 'https://pubmed.ncbi.nlm.nih.gov/15771560/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '123',
    slug: 'osteocalcin',
    name: 'Osteocalcin (Undercarboxylated)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Bone-matrix peptide hormone influencing insulin secretion, energy expenditure, and male fertility in models.',
    mechanism: 'Acts via GPRC6A receptors in pancreas, muscle, and testes; links bone remodeling to systemic metabolism.',
    evidence: [
      {
        title: 'Osteocalcin as an endocrine factor',
        year: 2009,
        source: 'PubMed',
        summary: 'Study of osteocalcin as metabolic hormone',
        url: 'https://pubmed.ncbi.nlm.nih.gov/19758163/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '124',
    slug: 'fgf21',
    name: 'FGF21 (Fibroblast Growth Factor-21)',
    regulatory_status: 'Research-only/Unapproved (analogs in trials)',
    summary: 'Liver-derived peptide-like hormone regulating glucose and lipid metabolism through β-Klotho/FGFR1c complexes.',
    mechanism: 'Activates FGFR1c–β-Klotho to enhance fatty acid oxidation, improve insulin sensitivity, and modulate energy expenditure.',
    evidence: [
      {
        title: 'FGF21 biology and therapeutic potential',
        year: 2018,
        source: 'PubMed',
        summary: 'Review of FGF21 in metabolic disease',
        url: 'https://pubmed.ncbi.nlm.nih.gov/30287044/',
      },
    ],
    common_adverse_effects: 'Research context; analogs in clinical trials',
    contraindications: 'Research context only',
    recommended_dosage: 'Clinical trial protocols; not yet approved',
  },
  {
    id: '125',
    slug: 'insulin',
    name: 'Insulin (Human)',
    regulatory_status: 'FDA-approved',
    summary: 'Core anabolic hormone regulating glucose uptake and metabolism; cornerstone of diabetes therapy and peptide biology.',
    mechanism: 'Binds insulin receptors to activate PI3K–Akt and MAPK pathways, promoting glucose uptake, glycogen synthesis, and lipid/protein anabolism.',
    evidence: [
      {
        title: 'Insulin: discovery and evolution of therapy (review)',
        year: 2021,
        source: 'PubMed',
        summary: 'Historical and clinical review of insulin therapy',
        url: 'https://pubmed.ncbi.nlm.nih.gov/34129677/',
      },
    ],
    common_adverse_effects: 'Hypoglycemia, weight gain, injection-site reactions',
    contraindications: 'Hypoglycemia unawareness; allergy (rare)',
    recommended_dosage: 'Individualized based on glucose monitoring; typical range 0.5-1.0 U/kg/day',
  },
  {
    id: '126',
    slug: 'glucagon',
    name: 'Glucagon (Therapeutic)',
    regulatory_status: 'FDA-approved',
    summary: 'Counter-regulatory hormone used for severe hypoglycemia and as a physiology probe for hepatic glucose output.',
    mechanism: 'Activates hepatic glucagon receptors, stimulating glycogenolysis and gluconeogenesis to raise plasma glucose.',
    evidence: [
      {
        title: 'Glucagon pharmacology and clinical applications',
        year: 2019,
        source: 'PubMed',
        summary: 'Review of glucagon in emergency and diagnostic use',
        url: 'https://pubmed.ncbi.nlm.nih.gov/30802373/',
      },
    ],
    common_adverse_effects: 'Nausea, transient hypertension, hyperglycemia',
    contraindications: 'Pheochromocytoma; insulinoma',
    recommended_dosage: 'Emergency: 1 mg IM/SC/IV for adults; 0.5 mg for children <20 kg',
  },
  {
    id: '127',
    slug: 'vasopressin',
    name: 'Vasopressin (Arginine Vasopressin, AVP)',
    regulatory_status: 'FDA-approved',
    summary: 'Nonapeptide regulating water retention and vascular tone; used in vasodilatory shock and diabetes insipidus.',
    mechanism: 'Stimulates V2 receptors in kidney for water reabsorption and V1 receptors for vasoconstriction.',
    evidence: [
      {
        title: 'Vasopressin: physiology and clinical use (review)',
        year: 2016,
        source: 'PubMed',
        summary: 'Comprehensive review of vasopressin biology and therapy',
        url: 'https://pubmed.ncbi.nlm.nih.gov/27469495/',
      },
    ],
    common_adverse_effects: 'Hyponatremia, vasoconstriction-related ischemia (dose-dependent)',
    contraindications: 'Chronic nephritis (relative); CAD (relative)',
    recommended_dosage: 'Diabetes insipidus: 5-10 units SC/IM 2-3x daily; Shock: 0.01-0.04 U/min IV',
  },
  {
    id: '128',
    slug: 'desmopressin',
    name: 'Desmopressin (DDAVP)',
    regulatory_status: 'FDA-approved',
    summary: 'Synthetic V2-selective vasopressin analog for diabetes insipidus, nocturia, and bleeding disorders.',
    mechanism: 'Activates renal V2 receptors to enhance water reabsorption; increases vWF and factor VIII release from endothelium.',
    evidence: [
      {
        title: 'Desmopressin pharmacology and clinical indications',
        year: 2012,
        source: 'PubMed',
        summary: 'Clinical pharmacology of desmopressin',
        url: 'https://pubmed.ncbi.nlm.nih.gov/22283409/',
      },
    ],
    common_adverse_effects: 'Hyponatremia, headache, nasal congestion (intranasal)',
    contraindications: 'Hyponatremia risk states; polydipsia',
    recommended_dosage: 'Diabetes insipidus: 10-40 mcg intranasal or 0.1-0.2 mg oral daily; Hemophilia: 0.3 mcg/kg IV',
  },
  {
    id: '129',
    slug: 'oxytocin',
    name: 'Oxytocin (Therapeutic)',
    regulatory_status: 'FDA-approved',
    summary: 'Endogenous uterotonic peptide used for labor induction, postpartum hemorrhage control, and milk let-down stimulation.',
    mechanism: 'Binds OXTR on uterine smooth muscle to increase Ca²⁺-mediated contractions; promotes myoepithelial contraction in mammary glands.',
    evidence: [
      {
        title: 'Oxytocin physiology and clinical uses',
        year: 2018,
        source: 'PubMed',
        summary: 'Review of oxytocin in obstetrics and neuroscience',
        url: 'https://pubmed.ncbi.nlm.nih.gov/29550136/',
      },
    ],
    common_adverse_effects: 'Uterine hyperstimulation, hyponatremia (water intoxication rare), hypotension (rapid infusion)',
    contraindications: 'Cephalopelvic disproportion; fetal distress',
    recommended_dosage: 'Labor induction: 1-2 mU/min IV, titrate; PPH prevention: 10-40 units in 1L IV after delivery',
  },
  {
    id: '130',
    slug: 'alpha-cgrp',
    name: 'α-CGRP',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Potent vasodilator neuropeptide released from trigeminal neurons; key mediator in migraine pathophysiology.',
    mechanism: 'Activates CGRP receptor complexes causing vasodilation and neurogenic inflammation.',
    evidence: [
      {
        title: 'CGRP signaling in migraine',
        year: 2019,
        source: 'PubMed',
        summary: 'Review of CGRP role in migraine pathogenesis',
        url: 'https://pubmed.ncbi.nlm.nih.gov/31177888/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '131',
    slug: 'melatonin',
    name: 'Melatonin (Circadian biology context)',
    regulatory_status: 'OTC supplement / hormone (not peptide but relevant to peptide circadian systems)',
    summary: 'Though not a peptide, melatonin is routinely studied alongside peptide regulators like epitalon for circadian and aging research.',
    mechanism: 'Binds MT1/MT2 receptors regulating circadian phase and sleep initiation.',
    evidence: [
      {
        title: 'Melatonin: circadian regulation overview',
        year: 2017,
        source: 'PubMed',
        summary: 'Overview of melatonin in circadian biology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/28867948/',
      },
    ],
    common_adverse_effects: 'Daytime drowsiness, headache (generally well tolerated)',
    contraindications: 'None specific; caution with sedatives',
    recommended_dosage: 'Sleep aid: 0.5-10 mg oral 30-60 min before bedtime',
  },
  {
    id: '132',
    slug: 'endothelin-1',
    name: 'Endothelin-1 (ET-1)',
    regulatory_status: 'Research-only/Unapproved (native peptide; antagonists approved)',
    summary: 'Native vasoconstrictor peptide; contrast target for approved endothelin receptor antagonists in pulmonary hypertension.',
    mechanism: 'Binds ETA/ETB receptors causing potent vasoconstriction and smooth muscle proliferation.',
    evidence: [
      {
        title: 'Endothelin system: physiology and pharmacology',
        year: 2017,
        source: 'PubMed',
        summary: 'Review of endothelin biology and therapeutic targeting',
        url: 'https://pubmed.ncbi.nlm.nih.gov/29127883/',
      },
    ],
    common_adverse_effects: 'Research context; antagonists (bosentan) are therapeutic',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only; clinical use via antagonists',
  },
  {
    id: '133',
    slug: 'collagen-tripeptides',
    name: 'Collagen-Derived Tripeptides (Pro-Hyp)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Di- and tripeptides released from collagen digestion proposed to stimulate fibroblast collagen synthesis.',
    mechanism: 'Bind oligopeptide transporters (PepT1/2) in dermal fibroblasts, inducing gene expression associated with ECM repair.',
    evidence: [
      {
        title: 'Pro-Hyp and fibroblast activity',
        year: 2010,
        source: 'PubMed',
        summary: 'Study of proline-hydroxyproline in skin biology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/20085668/',
      },
    ],
    common_adverse_effects: 'Generally well tolerated as nutritional supplement',
    contraindications: 'None specific in research contexts',
    recommended_dosage: 'Nutritional supplement context; 2.5-15 g daily in studies',
  },
  {
    id: '134',
    slug: 'adiponectin-fragments',
    name: 'Adiponectin (Peptide fragments)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Multimeric adipocyte-secreted protein; peptide fragments studied for metabolic and anti-inflammatory effects.',
    mechanism: 'Activates AdipoR1/R2 to enhance fatty acid oxidation and insulin sensitivity.',
    evidence: [
      {
        title: 'Adiponectin signaling and peptide mimetics',
        year: 2015,
        source: 'PubMed',
        summary: 'Study of adiponectin fragments and receptor activation',
        url: 'https://pubmed.ncbi.nlm.nih.gov/25733644/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '135',
    slug: 'pramlintide',
    name: 'Pramlintide (Symlin)',
    regulatory_status: 'FDA-approved',
    summary: 'Stable analog of human amylin used with mealtime insulin in diabetes to modulate post-prandial glucose and satiety.',
    mechanism: 'Activates amylin receptors to slow gastric emptying, suppress glucagon, and enhance satiety.',
    evidence: [
      {
        title: 'Pramlintide: mechanism and clinical data',
        year: 2005,
        source: 'PubMed',
        summary: 'Clinical pharmacology of pramlintide',
        url: 'https://pubmed.ncbi.nlm.nih.gov/16037232/',
      },
    ],
    common_adverse_effects: 'Nausea, hypoglycemia when mis-timed with insulin',
    contraindications: 'Gastroparesis; hypoglycemia unawareness',
    recommended_dosage: 'Type 1 DM: 15-60 mcg SC before meals; Type 2 DM: 60-120 mcg SC before meals',
  },
  {
    id: '136',
    slug: 'cgrp-antagonist-reference',
    name: 'CGRP Antagonist (Eptinezumab reference)',
    regulatory_status: 'FDA-approved (antibody therapeutic, peptide target reference)',
    summary: 'Humanized antibody against CGRP for migraine prevention; included to contextualize peptide–target relationships.',
    mechanism: 'Binds circulating CGRP preventing receptor activation; peptide target is endogenous vasodilator/neurotransmitter.',
    evidence: [
      {
        title: 'Anti-CGRP therapy and migraine pathophysiology',
        year: 2021,
        source: 'PubMed',
        summary: 'Review of CGRP-targeted migraine therapeutics',
        url: 'https://pubmed.ncbi.nlm.nih.gov/33627340/',
      },
    ],
    common_adverse_effects: 'Injection site reactions, constipation (mAb class effects)',
    contraindications: 'Hypersensitivity to monoclonal antibodies',
    recommended_dosage: 'Eptinezumab: 100 mg IV every 3 months for migraine prevention',
  },
  {
    id: '137',
    slug: 'pth-1-84',
    name: 'Parathyroid Hormone (1-84)',
    regulatory_status: 'FDA-approved',
    summary: 'Endogenous 84-amino-acid hormone regulating calcium and phosphate homeostasis; recombinant form used for hypoparathyroidism.',
    mechanism: 'Activates PTH1 receptors in bone and kidney to increase calcium reabsorption, stimulate osteoblast activity, and enhance vitamin D activation.',
    evidence: [
      {
        title: 'PTH physiology and replacement therapy',
        year: 2020,
        source: 'PubMed',
        summary: 'Review of PTH replacement in hypoparathyroidism',
        url: 'https://pubmed.ncbi.nlm.nih.gov/32056907/',
      },
    ],
    common_adverse_effects: 'Hypocalcemia on withdrawal, paresthesia, headache',
    contraindications: 'Bone malignancy; risk of osteosarcoma (class warning from animal studies)',
    recommended_dosage: 'Hypoparathyroidism: 50-100 mcg SC daily, titrated to calcium levels',
  },
  {
    id: '138',
    slug: 'igf-1',
    name: 'IGF-1 (Mecasermin)',
    regulatory_status: 'FDA-approved',
    summary: 'Single-chain peptide growth factor mediating many GH actions; recombinant mecasermin treats severe primary IGF-1 deficiency.',
    mechanism: 'Binds IGF-1 receptors triggering PI3K–Akt and MAPK cascades promoting growth, glucose uptake, and anabolism.',
    evidence: [
      {
        title: 'IGF-1 physiology and therapy',
        year: 2016,
        source: 'PubMed',
        summary: 'Review of IGF-1 biology and therapeutic use',
        url: 'https://pubmed.ncbi.nlm.nih.gov/27242299/',
      },
    ],
    common_adverse_effects: 'Hypoglycemia (main risk), tonsillar hypertrophy, jaw pain',
    contraindications: 'Active malignancy; closed epiphyses (if growth goal)',
    recommended_dosage: 'Severe primary IGF-1 deficiency: 0.04-0.12 mg/kg SC twice daily',
  },
  {
    id: '139',
    slug: 'angiotensin-ii',
    name: 'Angiotensin II (Giapreza)',
    regulatory_status: 'FDA-approved',
    summary: 'Synthetic Ang II infusion approved for raising blood pressure in distributive shock.',
    mechanism: 'Agonizes AT1 receptors causing vasoconstriction and aldosterone release to elevate mean arterial pressure.',
    evidence: [
      {
        title: 'Angiotensin II in distributive shock',
        year: 2017,
        source: 'PubMed',
        summary: 'Clinical trial of angiotensin II in vasodilatory shock',
        url: 'https://pubmed.ncbi.nlm.nih.gov/29287906/',
      },
    ],
    common_adverse_effects: 'Thromboembolic events, ischemia (class warnings)',
    contraindications: 'None absolute; use with caution in all shock states',
    recommended_dosage: 'Distributive shock: Start 20 ng/kg/min IV, titrate up to 80 ng/kg/min',
  },
  {
    id: '140',
    slug: 'leuprolide',
    name: 'Leuprolide (Lupron)',
    regulatory_status: 'FDA-approved',
    summary: 'Decapeptide GnRH agonist that causes initial LH/FSH stimulation followed by receptor desensitization and gonadal suppression.',
    mechanism: 'Continuous GnRH-receptor activation down-regulates pituitary receptors, reducing sex-steroid production.',
    evidence: [
      {
        title: 'Leuprolide pharmacology and clinical use (review)',
        year: 2019,
        source: 'PubMed',
        summary: 'Comprehensive review of leuprolide mechanism and applications',
        url: 'https://pubmed.ncbi.nlm.nih.gov/31261510/',
      },
    ],
    common_adverse_effects: 'Hot flashes, bone loss, mood changes',
    contraindications: 'Pregnancy; undiagnosed vaginal bleeding',
    recommended_dosage: 'Prostate cancer: 7.5 mg IM monthly or 22.5 mg every 3 months; Endometriosis: 3.75 mg IM monthly',
  },
  {
    id: '141',
    slug: 'goserelin',
    name: 'Goserelin (Zoladex)',
    regulatory_status: 'FDA-approved',
    summary: 'Long-acting GnRH agonist implant used for hormone-dependent cancers and endometriosis.',
    mechanism: 'Sustained GnRH-receptor stimulation causing LH/FSH suppression and sex-steroid down-regulation.',
    evidence: [
      {
        title: 'GnRH agonists in oncology and gynecology',
        year: 2016,
        source: 'PubMed',
        summary: 'Review of GnRH agonist use in cancer and reproductive medicine',
        url: 'https://pubmed.ncbi.nlm.nih.gov/27436460/',
      },
    ],
    common_adverse_effects: 'Hot flashes, bone loss, mood changes',
    contraindications: 'Pregnancy',
    recommended_dosage: 'Prostate/breast cancer: 3.6 mg SC every 28 days or 10.8 mg every 12 weeks',
  },
  {
    id: '142',
    slug: 'degarelix',
    name: 'Degarelix (Firmagon)',
    regulatory_status: 'FDA-approved',
    summary: 'Decapeptide GnRH antagonist that rapidly suppresses testosterone without initial surge.',
    mechanism: 'Competitively blocks GnRH receptors at pituitary, reducing LH/FSH release and downstream androgens.',
    evidence: [
      {
        title: 'Degarelix mechanism and clinical data',
        year: 2015,
        source: 'PubMed',
        summary: 'Clinical pharmacology of degarelix in prostate cancer',
        url: 'https://pubmed.ncbi.nlm.nih.gov/25630707/',
      },
    ],
    common_adverse_effects: 'Injection-site reactions, hot flashes',
    contraindications: 'None absolute; caution with QT prolongation risk',
    recommended_dosage: 'Advanced prostate cancer: 240 mg SC loading, then 80 mg SC monthly',
  },
  {
    id: '143',
    slug: 'carbetocin',
    name: 'Carbetocin (Duratocin)',
    regulatory_status: 'FDA-approved (cesarean use); global program for PPH prevention',
    summary: 'Longer-acting oxytocin analog for postpartum hemorrhage prevention and uterine atonia.',
    mechanism: 'Binds oxytocin receptors causing uterine smooth-muscle contraction; more stable than native oxytocin.',
    evidence: [
      {
        title: 'Carbetocin stability and PPH prevention',
        year: 2019,
        source: 'PubMed',
        summary: 'Study of carbetocin in postpartum hemorrhage prevention',
        url: 'https://pubmed.ncbi.nlm.nih.gov/31206549/',
      },
    ],
    common_adverse_effects: 'Flushing, nausea, mild hypotension',
    contraindications: 'Pregnancy before delivery (uterotonic risk)',
    recommended_dosage: 'PPH prevention: 100 mcg IV or IM single dose immediately after delivery',
  },
  {
    id: '144',
    slug: 'somapacitan',
    name: 'Somapacitan (Sogroya)',
    regulatory_status: 'FDA-approved',
    summary: 'Albumin-binding GH analog enabling once-weekly dosing for adult GH deficiency.',
    mechanism: 'Binds GH receptor to stimulate IGF-1 production; fatty-acid side chain confers reversible albumin binding for extended half-life.',
    evidence: [
      {
        title: 'Somapacitan pharmacology and weekly GH therapy',
        year: 2021,
        source: 'PubMed',
        summary: 'Clinical trial of weekly somapacitan vs daily GH',
        url: 'https://pubmed.ncbi.nlm.nih.gov/34585242/',
      },
    ],
    common_adverse_effects: 'Injection-site reactions, arthralgia, peripheral edema',
    contraindications: 'Active malignancy; acute critical illness',
    recommended_dosage: 'Adult GH deficiency: Start 1.5 mg SC weekly, titrate based on IGF-1 levels',
  },
  {
    id: '145',
    slug: 'cosyntropin',
    name: 'Cosyntropin (ACTH 1-24, Cortrosyn)',
    regulatory_status: 'FDA-approved (diagnostic)',
    summary: 'Synthetic ACTH fragment used to evaluate adrenal function in suspected insufficiency.',
    mechanism: 'Stimulates MC2R on adrenal cortex to trigger cortisol release; short sequence retains full biologic activity.',
    evidence: [
      {
        title: 'ACTH(1-24) stimulation testing standards',
        year: 2018,
        source: 'PubMed',
        summary: 'Guidelines for cosyntropin stimulation testing',
        url: 'https://pubmed.ncbi.nlm.nih.gov/29507669/',
      },
    ],
    common_adverse_effects: 'Transient flushing or nausea (rare)',
    contraindications: 'None specific for diagnostic use',
    recommended_dosage: 'ACTH stimulation test: 250 mcg IV or IM; measure cortisol at 0, 30, 60 min',
  },
  {
    id: '146',
    slug: 'crh',
    name: 'Corticotropin-Releasing Hormone (Corticorelin)',
    regulatory_status: 'FDA-approved (diagnostic formulation)',
    summary: 'Hypothalamic peptide that stimulates ACTH release from the pituitary and activates the stress axis.',
    mechanism: 'Binds CRF1 receptors on pituitary corticotrophs and central stress pathways, increasing ACTH and cortisol.',
    evidence: [
      {
        title: 'CRH physiology and diagnostic testing',
        year: 2019,
        source: 'PubMed',
        summary: 'Review of CRH in HPA axis and Cushing diagnosis',
        url: 'https://pubmed.ncbi.nlm.nih.gov/31585479/',
      },
    ],
    common_adverse_effects: 'Flushing, tachycardia in provocation testing',
    contraindications: 'None specific for diagnostic use',
    recommended_dosage: 'Cushing differential: 1 mcg/kg IV bolus; measure ACTH/cortisol at intervals',
  },
  {
    id: '147',
    slug: 'trh',
    name: 'Thyrotropin-Releasing Hormone (Protirelin)',
    regulatory_status: 'Research-only/Unapproved (used diagnostically in past)',
    summary: 'Tripeptide hypothalamic hormone that stimulates TSH and prolactin release from the anterior pituitary.',
    mechanism: 'Binds TRH receptors on thyrotrophs to trigger TSH secretion and thyroid axis activation.',
    evidence: [
      {
        title: 'TRH history and physiology',
        year: 2000,
        source: 'PubMed',
        summary: 'Historical review of TRH discovery and function',
        url: 'https://pubmed.ncbi.nlm.nih.gov/11080493/',
      },
    ],
    common_adverse_effects: 'Historical diagnostic use; minimal adverse effects',
    contraindications: 'Research context',
    recommended_dosage: 'Historical diagnostic: 200-500 mcg IV; now rarely used',
  },
  {
    id: '148',
    slug: 'c-peptide',
    name: 'C-Peptide',
    regulatory_status: 'FDA-approved (diagnostic)',
    summary: 'By-product of endogenous insulin production used to differentiate type 1 from type 2 diabetes and insulin use.',
    mechanism: 'Released equimolarly with endogenous insulin during proinsulin cleavage; reflects β-cell function.',
    evidence: [
      {
        title: 'C-peptide clinical interpretation',
        year: 2018,
        source: 'PubMed',
        summary: 'Review of C-peptide testing in diabetes diagnosis',
        url: 'https://pubmed.ncbi.nlm.nih.gov/30454677/',
      },
    ],
    common_adverse_effects: 'Diagnostic biomarker; not administered therapeutically',
    contraindications: 'Diagnostic context',
    recommended_dosage: 'Diagnostic measurement only; not dosed',
  },
  {
    id: '149',
    slug: 'bdnf-fragments',
    name: 'BDNF Peptide Fragments',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Short peptides modeled on BDNF loops that activate TrkB receptors to support neuronal survival and plasticity in models.',
    mechanism: 'Engage TrkB signaling cascade promoting synaptic growth and neuroprotection.',
    evidence: [
      {
        title: 'BDNF mimetic peptides and neuroprotection',
        year: 2016,
        source: 'PubMed',
        summary: 'Study of BDNF-derived peptides in neurodegeneration',
        url: 'https://pubmed.ncbi.nlm.nih.gov/27421705/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '150',
    slug: 'anp-1-30',
    name: 'ANP Fragment (1-30)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Shorter fragment of ANP retaining natriuretic activity with altered receptor specificity used in renal research.',
    mechanism: 'Activates NPR-A with modified kinetics to study structure-function relations of ANP.',
    evidence: [
      {
        title: 'ANP fragment bioactivity analysis',
        year: 2000,
        source: 'PubMed',
        summary: 'Study of ANP fragments and receptor binding',
        url: 'https://pubmed.ncbi.nlm.nih.gov/10998099/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '151',
    slug: 'pasireotide-lar',
    name: 'Pasireotide LAR (Signifor LAR)',
    regulatory_status: 'FDA-approved',
    summary: 'Long-acting multireceptor somatostatin analog for Cushing's disease and acromegaly maintenance therapy.',
    mechanism: 'Targets SSTR1–5 especially SSTR5 to suppress ACTH and GH secretion.',
    evidence: [
      {
        title: 'Long-acting pasireotide in Cushing's disease',
        year: 2015,
        source: 'PubMed',
        summary: 'Clinical trial of pasireotide LAR in Cushing disease',
        url: 'https://pubmed.ncbi.nlm.nih.gov/25974636/',
      },
    ],
    common_adverse_effects: 'Hyperglycemia, GI disturbances, cholelithiasis',
    contraindications: 'Uncontrolled diabetes; caution with hepatic impairment',
    recommended_dosage: 'Cushing disease: 10-40 mg IM every 4 weeks; Acromegaly: 40-60 mg IM every 4 weeks',
  },
  {
    id: '152',
    slug: 'pthrp',
    name: 'PTHrP (Parathyroid Hormone-Related Peptide)',
    regulatory_status: 'Research-only/Unapproved (analog abaloparatide approved)',
    summary: 'Widespread paracrine factor sharing receptor with PTH; regulates development, calcium transport, and cell proliferation.',
    mechanism: 'Activates PTH1 receptor with distinct bias toward cAMP pathways.',
    evidence: [
      {
        title: 'PTHrP biology and clinical implications',
        year: 2012,
        source: 'PubMed',
        summary: 'Review of PTHrP in development and malignancy',
        url: 'https://pubmed.ncbi.nlm.nih.gov/22924809/',
      },
    ],
    common_adverse_effects: 'Research context; basis for abaloparatide analog',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only; clinical use via approved analogs',
  },
  {
    id: '153',
    slug: 'cgrp-receptor-fragment',
    name: 'CGRP Receptor Fragment (Experimental)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Synthetic fragments of CGRP receptor used to study ligand-binding sites and antagonist development.',
    mechanism: 'Compete with native CGRP at CLR/RAMP complex interfaces to map binding epitopes.',
    evidence: [
      {
        title: 'CGRP receptor structure and ligand binding',
        year: 2020,
        source: 'PubMed',
        summary: 'Structural biology of CGRP receptor and antagonists',
        url: 'https://pubmed.ncbi.nlm.nih.gov/32457463/',
      },
    ],
    common_adverse_effects: 'Research tool; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '154',
    slug: 'octreotide-reference',
    name: 'Octreotide (Somatostatin analog reference)',
    regulatory_status: 'FDA-approved',
    summary: 'Synthetic octapeptide inhibiting GH and GI hormones; used here as educational comparison for multi-receptor analogs.',
    mechanism: 'Binds SSTR2/SSTR5 to inhibit endocrine and neuroendocrine secretions.',
    evidence: [
      {
        title: 'Somatostatin analog evolution',
        year: 2017,
        source: 'PubMed',
        summary: 'Review of somatostatin analog development and use',
        url: 'https://pubmed.ncbi.nlm.nih.gov/29083857/',
      },
    ],
    common_adverse_effects: 'GI disturbances, cholelithiasis, hyperglycemia',
    contraindications: 'None absolute; caution with bradycardia',
    recommended_dosage: 'Acromegaly: 100-600 mcg/day SC in 2-4 doses or 20-30 mg IM depot monthly',
  },
  {
    id: '155',
    slug: 'tirzepatide-revisited',
    name: 'Tirzepatide (Mounjaro, Zepbound)',
    regulatory_status: 'FDA-approved',
    summary: 'First-in-class dual incretin agonist combining GIP and GLP-1 receptor activation to improve glycemia and drive weight reduction.',
    mechanism: 'Stimulates both GIP and GLP-1 receptors to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite.',
    evidence: [
      {
        title: 'SURPASS trial series: tirzepatide efficacy',
        year: 2021,
        source: 'PubMed',
        summary: 'Clinical trials demonstrating tirzepatide efficacy in T2DM',
        url: 'https://pubmed.ncbi.nlm.nih.gov/34170647/',
      },
    ],
    common_adverse_effects: 'GI upset (nausea, vomiting), decreased appetite',
    contraindications: 'MTC/MEN2 history; pancreatitis (precaution)',
    recommended_dosage: 'T2DM/Obesity: Start 2.5 mg SC weekly, titrate up to 15 mg weekly',
  },
  {
    id: '156',
    slug: 'danuglipron',
    name: 'Danuglipron (GLP-1 mimetic reference)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Small-molecule GLP-1 receptor agonist (non-peptidic) referenced here for educational contrast with true peptide agonists.',
    mechanism: 'Engages GLP-1R to mimic incretin signaling without peptide backbone; demonstrates transition from peptide to peptidomimetic.',
    evidence: [
      {
        title: 'Oral GLP-1 receptor agonists design review',
        year: 2023,
        source: 'PubMed',
        summary: 'Review of oral GLP-1 agonist development',
        url: 'https://pubmed.ncbi.nlm.nih.gov/37602710/',
      },
    ],
    common_adverse_effects: 'Research context; clinical trial phase',
    contraindications: 'Research context',
    recommended_dosage: 'Clinical trial protocols only',
  },
  {
    id: '157',
    slug: 'gdf15',
    name: 'GDF15 (Growth Differentiation Factor 15)',
    regulatory_status: 'Research-only/Unapproved (analogs in trials)',
    summary: 'Endocrine stress hormone acting on the brainstem GFRAL receptor to suppress appetite and alter energy expenditure.',
    mechanism: 'Binds GFRAL/RET receptor complex in the area postrema and nucleus tractus solitarius, activating anorexigenic signaling.',
    evidence: [
      {
        title: 'GDF15 and energy homeostasis (review)',
        year: 2020,
        source: 'PubMed',
        summary: 'Review of GDF15 biology and metabolic effects',
        url: 'https://pubmed.ncbi.nlm.nih.gov/31949230/',
      },
    ],
    common_adverse_effects: 'Research context; analogs in development',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '158',
    slug: 'tesofensine-conjugates',
    name: 'Tesofensine Peptidic Conjugates',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Hybrid constructs linking monoamine reuptake inhibition with peptide sequences to target metabolic pathways.',
    mechanism: 'Designed to engage CNS monoamine systems while modulating peripheral peptide signaling; experimental concept only.',
    evidence: [
      {
        title: 'Hybrid peptide–neurotransmitter approaches (concept review)',
        year: 2018,
        source: 'PubMed',
        summary: 'Review of hybrid peptide-neurotransmitter strategies',
        url: 'https://pubmed.ncbi.nlm.nih.gov/30371549/',
      },
    ],
    common_adverse_effects: 'Research context; experimental compounds',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '159',
    slug: 'ghrelin-antagonists',
    name: 'Ghrelin Antagonist Peptides',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Synthetic antagonists and inverse agonists of the ghrelin receptor studied for appetite suppression and metabolic modulation.',
    mechanism: 'Block or inverse-activate GHSR-1a to blunt hunger signaling and GH pulses.',
    evidence: [
      {
        title: 'Ghrelin receptor antagonism and appetite',
        year: 2014,
        source: 'PubMed',
        summary: 'Study of ghrelin antagonists in appetite control',
        url: 'https://pubmed.ncbi.nlm.nih.gov/24411732/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '160',
    slug: 'adipotide',
    name: 'Adipotide (FTP-11)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Targeted peptide conjugate that selectively binds adipose vasculature, triggering apoptosis and fat reduction in animals.',
    mechanism: 'Recognizes prohibitin on adipose endothelium, delivering a KLAKLAK proapoptotic motif disrupting mitochondrial membranes.',
    evidence: [
      {
        title: 'Adipotide preclinical outcomes',
        year: 2012,
        source: 'PubMed',
        summary: 'Preclinical study of adipotide in obesity models',
        url: 'https://pubmed.ncbi.nlm.nih.gov/22388087/',
      },
    ],
    common_adverse_effects: 'Research context; renal toxicity concerns in preclinical studies',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '161',
    slug: 'rgd-peptides',
    name: 'RGD-Motif Peptides',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Short tripeptide motifs that recognize integrins (e.g., αvβ3, α5β1), used in regenerative medicine and targeted drug delivery.',
    mechanism: 'Bind RGD-recognizing integrins on endothelial and ECM-adhesive cells to modulate angiogenesis and cell attachment.',
    evidence: [
      {
        title: 'Integrin-binding RGD peptides in biomedicine',
        year: 2017,
        source: 'PubMed',
        summary: 'Review of RGD peptides in biomaterials and drug delivery',
        url: 'https://pubmed.ncbi.nlm.nih.gov/28812224/',
      },
    ],
    common_adverse_effects: 'Research context; biomaterial applications',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '162',
    slug: 'thymosin-beta-15',
    name: 'Thymosin Beta-15',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Thymosin family peptide implicated in tumor cell motility and tissue remodeling; studied as biomarker candidate.',
    mechanism: 'Binds G-actin and modulates cytoskeleton dynamics influencing cell migration and angiogenesis.',
    evidence: [
      {
        title: 'Thymosin beta-15 and cancer progression',
        year: 2008,
        source: 'PubMed',
        summary: 'Study of thymosin beta-15 in cancer cell motility',
        url: 'https://pubmed.ncbi.nlm.nih.gov/18594887/',
      },
    ],
    common_adverse_effects: 'Research context; biomarker studies',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '163',
    slug: 'dermorphin',
    name: 'Dermorphin',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Potent μ-opioid agonist peptide from amphibian skin, studied for receptor selectivity and bias.',
    mechanism: 'Activates μ-opioid receptor with high affinity; shorter and more potent than endorphins.',
    evidence: [
      {
        title: 'Dermorphin pharmacology',
        year: 1982,
        source: 'PubMed',
        summary: 'Early characterization of dermorphin opioid activity',
        url: 'https://pubmed.ncbi.nlm.nih.gov/6282216/',
      },
    ],
    common_adverse_effects: 'Research context; potent opioid effects',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '164',
    slug: 'deltorphin-ii',
    name: 'Deltorphin II',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Amphibian peptide with high δ-opioid receptor selectivity used to study analgesic receptor subtype functions.',
    mechanism: 'Selective δ-opioid receptor agonist producing potent analgesia in experimental models.',
    evidence: [
      {
        title: 'Deltorphin and δ-opioid receptor selectivity',
        year: 1991,
        source: 'PubMed',
        summary: 'Characterization of deltorphin receptor selectivity',
        url: 'https://pubmed.ncbi.nlm.nih.gov/1666992/',
      },
    ],
    common_adverse_effects: 'Research context; delta-opioid effects',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '165',
    slug: 'bq-123',
    name: 'BQ-123 (Endothelin Antagonist)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Cyclic pentapeptide selectively blocking ETA receptors, benchmark tool in endothelin biology.',
    mechanism: 'Competitively inhibits ET-1 binding at ETA receptors, preventing vasoconstriction and proliferation.',
    evidence: [
      {
        title: 'BQ-123: selective ETA receptor antagonist',
        year: 1992,
        source: 'PubMed',
        summary: 'Development of BQ-123 as selective ETA antagonist',
        url: 'https://pubmed.ncbi.nlm.nih.gov/1313000/',
      },
    ],
    common_adverse_effects: 'Research tool; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '166',
    slug: 'angiogenin-fragments',
    name: 'Angiogenin Peptide Fragments',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Stress-activated angiogenin cleavage products acting as signaling peptides for cytoprotection and translation control.',
    mechanism: 'Trigger formation of stress granules and reduce global translation, promoting cell survival under stress.',
    evidence: [
      {
        title: 'Angiogenin and tRNA-derived stress fragments',
        year: 2014,
        source: 'PubMed',
        summary: 'Study of angiogenin-derived signaling fragments',
        url: 'https://pubmed.ncbi.nlm.nih.gov/24442690/',
      },
    ],
    common_adverse_effects: 'Research context; cell stress biology',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '167',
    slug: 'thymosin-alpha-11',
    name: 'Thymosin Alpha-11',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Newly characterized thymic peptide with immunomodulatory activity under investigation.',
    mechanism: 'Potentially interacts with T-cell regulatory networks and cytokine balance; exact receptor unknown.',
    evidence: [
      {
        title: 'Novel thymosin peptides: discovery landscape',
        year: 2018,
        source: 'PubMed',
        summary: 'Discovery and characterization of novel thymosin peptides',
        url: 'https://pubmed.ncbi.nlm.nih.gov/29267518/',
      },
    ],
    common_adverse_effects: 'Research context; early characterization phase',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '168',
    slug: 'ghsr-biased-peptides',
    name: 'GHSR-Biased Peptides',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Engineered GH-releasing peptides designed for receptor bias toward metabolic rather than hunger pathways.',
    mechanism: 'Activate GHSR-1a selectively coupling to Gq vs Gi/o to modulate GH release without strong orexigenic signals.',
    evidence: [
      {
        title: 'Biased ghrelin receptor agonism',
        year: 2021,
        source: 'PubMed',
        summary: 'Study of biased signaling at ghrelin receptor',
        url: 'https://pubmed.ncbi.nlm.nih.gov/34168322/',
      },
    ],
    common_adverse_effects: 'Research context; biased signaling studies',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '169',
    slug: 'irgd',
    name: 'iRGD (Tumor-Homing Peptide)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Modified RGD peptide that enhances drug penetration into tumors by sequentially binding integrins and neuropilin-1.',
    mechanism: 'Binds αv integrins on tumor endothelium, then undergoes proteolytic cleavage exposing CendR motif that binds neuropilin-1, increasing tissue permeability.',
    evidence: [
      {
        title: 'iRGD and tumor-penetrating peptide mechanisms',
        year: 2011,
        source: 'PubMed',
        summary: 'Discovery and mechanism of iRGD tumor-penetrating peptide',
        url: 'https://pubmed.ncbi.nlm.nih.gov/21474821/',
      },
    ],
    common_adverse_effects: 'Research context; drug delivery studies',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '170',
    slug: 'hcg',
    name: 'Human Chorionic Gonadotropin (hCG)',
    regulatory_status: 'FDA-approved',
    summary: 'Placental glycoprotein hormone used clinically to mimic LH bioactivity in assisted reproduction and selected endocrine indications.',
    mechanism: 'Binds LH/CG receptor on gonadal cells to stimulate steroidogenesis and ovulatory/androgenic signaling.',
    evidence: [
      {
        title: 'hCG clinical use & physiology (review)',
        year: 2012,
        source: 'PubMed',
        summary: 'Comprehensive review of hCG physiology and clinical applications',
        url: 'https://pubmed.ncbi.nlm.nih.gov/22480951/',
      },
    ],
    common_adverse_effects: 'Injection-site discomfort, headache, ovarian enlargement (ART context)',
    contraindications: 'Hormone-sensitive tumors; pregnancy (non-ART contexts)',
    recommended_dosage: 'ART ovulation trigger: 5,000-10,000 units IM once; Hypogonadism: 1,000-2,000 units IM 2-3x/week',
  },
  {
    id: '171',
    slug: 'choriogonadotropin-alfa',
    name: 'Choriogonadotropin alfa (Ovidrel)',
    regulatory_status: 'FDA-approved',
    summary: 'Recombinant hCG with consistent potency and reduced batch variability vs urinary products, widely used to trigger final oocyte maturation.',
    mechanism: 'LH/CG receptor agonism on theca/granulosa cells to induce ovulatory cascade.',
    evidence: [
      {
        title: 'rhCG in assisted reproduction (review)',
        year: 2005,
        source: 'PubMed',
        summary: 'Review of recombinant hCG in ART protocols',
        url: 'https://pubmed.ncbi.nlm.nih.gov/15672989/',
      },
    ],
    common_adverse_effects: 'Injection-site reactions, headache, nausea',
    contraindications: 'Hormone-dependent tumors; primary ovarian failure',
    recommended_dosage: 'ART: 250 mcg SC single dose when follicles are mature',
  },
  {
    id: '172',
    slug: 'hpl',
    name: 'Human Placental Lactogen (hPL)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Placental hormone modulating maternal insulin resistance, lipolysis, and mammary development to prioritize fetal nutrient supply.',
    mechanism: 'Binds prolactin/GH-family receptors, shifting maternal metabolism toward lipolysis and sparing glucose for the fetus.',
    evidence: [
      {
        title: 'hPL physiology (review)',
        year: 2010,
        source: 'PubMed',
        summary: 'Review of placental lactogen in pregnancy metabolism',
        url: 'https://pubmed.ncbi.nlm.nih.gov/20650842/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '173',
    slug: 'placental-crh',
    name: 'Placental CRH',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'CRH produced by the placenta, rising exponentially in late gestation and implicated in timing of parturition and stress biology.',
    mechanism: 'Binds CRF1 receptors, amplifying maternal–fetal HPA-axis signaling and prostaglandin pathways near term.',
    evidence: [
      {
        title: 'Placental CRH and the timing of birth',
        year: 2006,
        source: 'PubMed',
        summary: 'Study of placental CRH in labor timing',
        url: 'https://pubmed.ncbi.nlm.nih.gov/16981945/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '174',
    slug: 'triptorelin',
    name: 'Triptorelin (Trelstar)',
    regulatory_status: 'FDA-approved',
    summary: 'Depot GnRH agonist causing down-regulation of LH/FSH after an initial flare; used for androgen suppression and CPP.',
    mechanism: 'Continuous agonism desensitizes pituitary GnRH receptors, suppressing gonadotropin release.',
    evidence: [
      {
        title: 'Triptorelin in androgen deprivation',
        year: 2012,
        source: 'PubMed',
        summary: 'Review of triptorelin in prostate cancer treatment',
        url: 'https://pubmed.ncbi.nlm.nih.gov/22726263/',
      },
    ],
    common_adverse_effects: 'Hot flashes, bone density loss (long term), injection-site reactions',
    contraindications: 'Pregnancy',
    recommended_dosage: 'Prostate cancer: 3.75 mg IM monthly or 11.25 mg IM every 3 months; CPP: 22.5 mg IM every 6 months',
  },
  {
    id: '175',
    slug: 'nafarelin',
    name: 'Nafarelin (Synarel)',
    regulatory_status: 'FDA-approved',
    summary: 'Intranasal GnRH agonist for endometriosis and central precocious puberty; demonstrates non-injectable peptide delivery.',
    mechanism: 'Chronic GnRH receptor stimulation → LH/FSH suppression.',
    evidence: [
      {
        title: 'Nafarelin in endometriosis/CPP',
        year: 1989,
        source: 'PubMed',
        summary: 'Early clinical studies of nafarelin',
        url: 'https://pubmed.ncbi.nlm.nih.gov/2654557/',
      },
    ],
    common_adverse_effects: 'Rhinitis/irritation, hot flashes, mood changes',
    contraindications: 'Pregnancy; undiagnosed vaginal bleeding',
    recommended_dosage: 'Endometriosis: 200 mcg (one spray) per nostril twice daily for up to 6 months',
  },
  {
    id: '176',
    slug: 'histrelin',
    name: 'Histrelin (Supprelin LA, Vantas)',
    regulatory_status: 'FDA-approved',
    summary: 'Subcutaneous implant GnRH agonist for long-term suppression, notably CPP; historically for prostate cancer (Vantas).',
    mechanism: 'Continuous GnRH receptor agonism causing pituitary desensitization.',
    evidence: [
      {
        title: 'Histrelin implant in CPP',
        year: 2009,
        source: 'PubMed',
        summary: 'Study of histrelin implant in central precocious puberty',
        url: 'https://pubmed.ncbi.nlm.nih.gov/19549752/',
      },
    ],
    common_adverse_effects: 'Implant-site reactions, hot flashes, bone density loss with prolonged use',
    contraindications: 'Pregnancy',
    recommended_dosage: 'CPP: 50 mg implant SC annually; Prostate cancer: 50 mg implant SC annually',
  },
  {
    id: '177',
    slug: 'cetrorelix',
    name: 'Cetrorelix (Cetrotide)',
    regulatory_status: 'FDA-approved',
    summary: 'GnRH antagonist used acutely in ART to prevent premature LH surge without the initial flare of agonists.',
    mechanism: 'Competitive blockade of pituitary GnRH receptors, rapidly reducing LH/FSH.',
    evidence: [
      {
        title: 'GnRH antagonists in ART (review)',
        year: 1999,
        source: 'PubMed',
        summary: 'Review of GnRH antagonist protocols in assisted reproduction',
        url: 'https://pubmed.ncbi.nlm.nih.gov/10577675/',
      },
    ],
    common_adverse_effects: 'Injection-site reactions, nausea, headache',
    contraindications: 'Pregnancy; hypersensitivity to GnRH analogs',
    recommended_dosage: 'ART: 0.25 mg SC daily or 3 mg SC single dose during ovarian stimulation',
  },
  {
    id: '178',
    slug: 'ganirelix',
    name: 'Ganirelix (Antagon)',
    regulatory_status: 'FDA-approved',
    summary: 'Short-acting antagonist for prevention of premature LH surge during ovarian stimulation.',
    mechanism: 'Blocks GnRH receptors on pituitary gonadotrophs, suppressing LH/FSH swiftly.',
    evidence: [
      {
        title: 'Antagonist vs agonist protocols in ART',
        year: 2005,
        source: 'PubMed',
        summary: 'Comparison of GnRH antagonist and agonist protocols',
        url: 'https://pubmed.ncbi.nlm.nih.gov/15753009/',
      },
    ],
    common_adverse_effects: 'Injection-site reactions, headache',
    contraindications: 'Pregnancy; known hypersensitivity',
    recommended_dosage: 'ART: 250 mcg SC daily during ovarian stimulation, starting day 5-6',
  },
  {
    id: '179',
    slug: 'atosiban',
    name: 'Atosiban (Tractocile)',
    regulatory_status: 'EU/Global-approved (not FDA-approved)',
    summary: 'Peptide antagonist of OXTR and V1a receptors used as a tocolytic to inhibit preterm uterine contractions outside the US.',
    mechanism: 'Blocks oxytocin-mediated uterine contractions; some V1a antagonism may reduce vasoconstriction.',
    evidence: [
      {
        title: 'Atosiban for preterm labor (Cochrane review)',
        year: 2013,
        source: 'PubMed',
        summary: 'Systematic review of atosiban for preterm labor',
        url: 'https://pubmed.ncbi.nlm.nih.gov/23450550/',
      },
    ],
    common_adverse_effects: 'Nausea, headache, injection-site reactions',
    contraindications: 'Gestational age or maternal–fetal conditions where delay is unsafe',
    recommended_dosage: 'Preterm labor: 6.75 mg IV bolus, then 300 mcg/min × 3h, then 100 mcg/min up to 45h',
  },
  {
    id: '180',
    slug: 'serelaxin',
    name: 'Serelaxin (RLX030)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Recombinant Relaxin-2 studied for acute heart failure and obstetric indications; large trials showed mixed outcomes.',
    mechanism: 'Activates RXFP1 to promote vasodilation, antifibrotic signaling, and renal perfusion improvements.',
    evidence: [
      {
        title: 'Serelaxin in AHF: outcomes',
        year: 2014,
        source: 'PubMed',
        summary: 'Clinical trial of serelaxin in acute heart failure',
        url: 'https://pubmed.ncbi.nlm.nih.gov/25127136/',
      },
    ],
    common_adverse_effects: 'Headache, hypotension',
    contraindications: 'Research context',
    recommended_dosage: 'Clinical trial protocols only',
  },
  {
    id: '181',
    slug: 'inhibin-a',
    name: 'Inhibin A',
    regulatory_status: 'Research/Diagnostic (maternal serum screening)',
    summary: 'Ovarian/placental peptide hormone that suppresses pituitary FSH; maternal serum marker used in aneuploidy screening.',
    mechanism: 'Binds activin receptors/coreceptors to antagonize activin signaling, reducing FSH synthesis.',
    evidence: [
      {
        title: 'Inhibin/activin system overview',
        year: 2006,
        source: 'PubMed',
        summary: 'Review of inhibin and activin in reproduction',
        url: 'https://pubmed.ncbi.nlm.nih.gov/17011529/',
      },
    ],
    common_adverse_effects: 'Diagnostic biomarker; not administered therapeutically',
    contraindications: 'Diagnostic context',
    recommended_dosage: 'Diagnostic measurement only; not dosed',
  },
  {
    id: '182',
    slug: 'activin-a',
    name: 'Activin A',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Pituitary/gonadal regulator that stimulates FSH synthesis and influences folliculogenesis, implantation, and placental function.',
    mechanism: 'Binds activin receptors (ActRIIA/IIB, ALK4/7) to activate SMAD2/3 signaling.',
    evidence: [
      {
        title: 'Activin in reproduction (review)',
        year: 2007,
        source: 'PubMed',
        summary: 'Review of activin role in reproductive biology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/17287271/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '183',
    slug: 'prolactin',
    name: 'Prolactin (PRL)',
    regulatory_status: 'Research/Diagnostic',
    summary: 'Anterior pituitary hormone essential for lactation and with pleiotropic roles in immune modulation and metabolism.',
    mechanism: 'Binds PRLR (class I cytokine receptor) to activate JAK2/STAT5 and MAPK pathways; promotes mammary development and milk synthesis.',
    evidence: [
      {
        title: 'Prolactin physiology and clinical aspects',
        year: 2010,
        source: 'PubMed',
        summary: 'Comprehensive review of prolactin biology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/20833310/',
      },
    ],
    common_adverse_effects: 'Diagnostic biomarker; not administered therapeutically',
    contraindications: 'Diagnostic context',
    recommended_dosage: 'Diagnostic measurement only; not dosed',
  },
  {
    id: '184',
    slug: 'hcg-beta-core',
    name: 'hCG β-Core Fragment',
    regulatory_status: 'Diagnostic/Research',
    summary: 'Urinary degradation product of hCG β-subunit used in certain trophoblastic disease and pregnancy assessments.',
    mechanism: 'Derived from proteolysis of β-hCG; detected by specific immunoassays.',
    evidence: [
      {
        title: 'hCG variants and clinical assays (review)',
        year: 2010,
        source: 'PubMed',
        summary: 'Review of hCG isoforms in clinical diagnostics',
        url: 'https://pubmed.ncbi.nlm.nih.gov/20628076/',
      },
    ],
    common_adverse_effects: 'Diagnostic biomarker only',
    contraindications: 'Diagnostic context',
    recommended_dosage: 'Diagnostic measurement only; not dosed',
  },
  {
    id: '185',
    slug: 'placental-lactogen-variants',
    name: 'Placental Lactogen-Like Peptides',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Variant placental GH/PRL-family peptides with overlapping metabolic and mammotropic effects; characterized in molecular studies.',
    mechanism: 'Interact with PRLR/GHR pathways to modulate maternal metabolism and mammary gland signaling.',
    evidence: [
      {
        title: 'Placental GH/PRL family evolution',
        year: 2011,
        source: 'PubMed',
        summary: 'Study of placental hormone family evolution',
        url: 'https://pubmed.ncbi.nlm.nih.gov/21138777/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '186',
    slug: 'kisspeptin-analogs',
    name: 'Kisspeptin Analogs',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Engineered kisspeptin peptides designed to modulate GnRH neuron activation with improved stability/PK vs native fragments.',
    mechanism: 'Agonize KISS1R (GPR54) on GnRH neurons, triggering LH/FSH release; analogs aim for controlled pulse timing and duration.',
    evidence: [
      {
        title: 'Kisspeptin for reproductive induction (overview)',
        year: 2019,
        source: 'PubMed',
        summary: 'Review of kisspeptin in fertility research',
        url: 'https://pubmed.ncbi.nlm.nih.gov/31420391/',
      },
    ],
    common_adverse_effects: 'Transient flushing or headache in infusion studies',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '187',
    slug: 'argireline',
    name: 'Acetyl Hexapeptide-8 (Argireline)',
    regulatory_status: 'Research-only/Unapproved (cosmetic ingredient)',
    summary: 'Synthetic peptide that mimics SNAP-25 N-terminal domain to modulate neurotransmitter release at the neuromuscular junction, marketed for expression line cosmetic effects.',
    mechanism: 'Interferes with SNARE complex formation, reducing vesicle exocytosis in vitro; acts superficially when applied topically.',
    evidence: [
      {
        title: 'Acetyl Hexapeptide-8 mechanism and cosmetic data',
        year: 2017,
        source: 'PubMed',
        summary: 'Study of argireline in cosmetic applications',
        url: 'https://pubmed.ncbi.nlm.nih.gov/28674291/',
      },
    ],
    common_adverse_effects: 'Generally well tolerated in topical formulations',
    contraindications: 'None specific for cosmetic use',
    recommended_dosage: 'Cosmetic formulations: typically 5-10% concentration',
  },
  {
    id: '188',
    slug: 'matrixyl',
    name: 'Matrixyl (Palmitoyl Pentapeptide-4)',
    regulatory_status: 'Research-only/Unapproved (cosmetic ingredient)',
    summary: 'Peptide fragment from collagen type I sequence that stimulates ECM repair signaling in skin fibroblasts.',
    mechanism: 'Binds cell-surface receptors influencing TGF-β and integrin signaling, stimulating collagen and fibronectin synthesis.',
    evidence: [
      {
        title: 'Matrixyl peptides and skin matrix regeneration',
        year: 2008,
        source: 'PubMed',
        summary: 'Study of matrixyl in skin rejuvenation',
        url: 'https://pubmed.ncbi.nlm.nih.gov/18492053/',
      },
    ],
    common_adverse_effects: 'Generally well tolerated in cosmetic formulations',
    contraindications: 'None specific for cosmetic use',
    recommended_dosage: 'Cosmetic formulations: typically 3-6% concentration',
  },
  {
    id: '189',
    slug: 'matrixyl-3000',
    name: 'Matrixyl 3000',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Blend of collagen-stimulating and anti-inflammatory peptides developed for skin rejuvenation.',
    mechanism: 'Combines matrikine peptides to upregulate ECM proteins while modulating cytokine expression in fibroblasts.',
    evidence: [
      {
        title: 'Signal peptides in cosmetic science (overview)',
        year: 2013,
        source: 'PubMed',
        summary: 'Review of signal peptides in dermatology',
        url: 'https://pubmed.ncbi.nlm.nih.gov/24301263/',
      },
    ],
    common_adverse_effects: 'Generally well tolerated in cosmetic formulations',
    contraindications: 'None specific for cosmetic use',
    recommended_dosage: 'Cosmetic formulations: manufacturer-specific concentrations',
  },
  {
    id: '190',
    slug: 'ghk-cu-revisited',
    name: 'Copper Tripeptide-1 (GHK-Cu)',
    regulatory_status: 'Research-only/Unapproved (cosmetic/topical use)',
    summary: 'Endogenous tripeptide–copper complex that promotes wound healing, angiogenesis, and antioxidant defense in skin.',
    mechanism: 'Upregulates metalloproteinases and growth factors while stimulating collagen and glycosaminoglycan synthesis.',
    evidence: [
      {
        title: 'GHK-Cu molecular and cosmetic effects',
        year: 2015,
        source: 'PMC',
        summary: 'Comprehensive review of GHK-Cu mechanisms',
        url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/',
      },
    ],
    common_adverse_effects: 'Generally well tolerated; mild irritation possible',
    contraindications: 'None specific for topical use',
    recommended_dosage: 'Cosmetic formulations: 0.05-1% concentration',
  },
  {
    id: '191',
    slug: 'oligopeptide-68',
    name: 'Oligopeptide-68',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Synthetic peptide used in pigment-evening skincare for tyrosinase inhibition and melanocyte signal modulation.',
    mechanism: 'Downregulates MC1R and MITF transcription factors; reduces melanin synthesis in melanocytes.',
    evidence: [
      {
        title: 'Peptide-based skin depigmenting agents',
        year: 2017,
        source: 'PubMed',
        summary: 'Study of peptide tyrosinase inhibitors',
        url: 'https://pubmed.ncbi.nlm.nih.gov/29034823/',
      },
    ],
    common_adverse_effects: 'Generally well tolerated in cosmetic formulations',
    contraindications: 'None specific for cosmetic use',
    recommended_dosage: 'Cosmetic formulations: manufacturer-specific concentrations',
  },
  {
    id: '192',
    slug: 'defensin-mimetics',
    name: 'Defensin Mimetic Peptides',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Synthetic analogs of β-defensins designed for increased stability and wound-healing enhancement.',
    mechanism: 'Cationic peptides that disrupt microbial membranes and modulate keratinocyte migration and immune signaling.',
    evidence: [
      {
        title: 'Defensins in tissue repair',
        year: 2015,
        source: 'PubMed',
        summary: 'Review of defensin role in wound healing',
        url: 'https://pubmed.ncbi.nlm.nih.gov/26427404/',
      },
    ],
    common_adverse_effects: 'Research context; generally well tolerated',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '193',
    slug: 'epithalon',
    name: 'Epithalon (Epitalon)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Short synthetic peptide studied for potential telomerase activation and circadian rhythm regulation.',
    mechanism: 'Proposed modulation of melatonin secretion and chromatin stability genes in vitro.',
    evidence: [
      {
        title: 'Epithalon and telomerase hypotheses',
        year: 2015,
        source: 'PubMed',
        summary: 'Study of epithalon in aging research',
        url: 'https://pubmed.ncbi.nlm.nih.gov/25824742/',
      },
    ],
    common_adverse_effects: 'Research context; limited clinical data',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '194',
    slug: 'imiquimod-peptide-conjugates',
    name: 'Imiquimod Peptide Conjugates',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Peptide–TLR7 agonist hybrids designed to enhance antigen-specific immunity in experimental vaccines.',
    mechanism: 'Combines peptide antigen epitopes with toll-like receptor–activating motifs to boost dendritic-cell stimulation.',
    evidence: [
      {
        title: 'TLR7 adjuvant peptide conjugates',
        year: 2018,
        source: 'PubMed',
        summary: 'Study of TLR7 agonist-peptide conjugates in vaccines',
        url: 'https://pubmed.ncbi.nlm.nih.gov/30514376/',
      },
    ],
    common_adverse_effects: 'Research context; vaccine adjuvant studies',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '195',
    slug: 'padre',
    name: 'PADRE Peptide',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Universal T-helper epitope peptide used in peptide vaccine constructs to enhance MHC class II presentation across HLA types.',
    mechanism: 'Binds broadly to HLA-DR molecules, providing strong CD4+ T-cell help to linked antigens.',
    evidence: [
      {
        title: 'PADRE universal helper epitope in vaccines',
        year: 2000,
        source: 'PubMed',
        summary: 'Development of PADRE as universal vaccine helper',
        url: 'https://pubmed.ncbi.nlm.nih.gov/10772985/',
      },
    ],
    common_adverse_effects: 'Research context; vaccine adjuvant use',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '196',
    slug: 'melittin',
    name: 'Melittin',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Principal peptide in bee venom studied for lytic, antimicrobial, and anti-inflammatory effects; incorporated in nanoparticle oncology research.',
    mechanism: 'Disrupts lipid bilayers and modulates PLA2/COX signaling at low concentrations.',
    evidence: [
      {
        title: 'Melittin in biomedicine (review)',
        year: 2019,
        source: 'PubMed',
        summary: 'Comprehensive review of melittin applications',
        url: 'https://pubmed.ncbi.nlm.nih.gov/31093323/',
      },
    ],
    common_adverse_effects: 'Research context; cytotoxic at high concentrations',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only; controlled delivery systems',
  },
  {
    id: '197',
    slug: 'pam3csk4',
    name: 'Lipopeptide Vaccine Adjuvants (Pam3CSK4)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Synthetic triacylated lipopeptides mimicking bacterial lipoproteins; used to activate innate immune signaling in vaccines.',
    mechanism: 'Bind TLR2/TLR1 heterodimers, triggering NF-κB and cytokine induction.',
    evidence: [
      {
        title: 'Lipopeptide adjuvants in modern vaccine design',
        year: 2017,
        source: 'PubMed',
        summary: 'Review of lipopeptide vaccine adjuvants',
        url: 'https://pubmed.ncbi.nlm.nih.gov/28217239/',
      },
    ],
    common_adverse_effects: 'Research context; adjuvant reactogenicity',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '198',
    slug: 'tat-peptide',
    name: 'Tat Peptide (HIV-1 Tat 47-57)',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Cationic peptide sequence from HIV-1 Tat protein enabling translocation of attached cargo across cellular membranes.',
    mechanism: 'Rich in arginine/lysine residues, interacts with phospholipid bilayers and heparan sulfates to internalize macromolecules.',
    evidence: [
      {
        title: 'Cell-penetrating peptides and Tat mechanism',
        year: 2010,
        source: 'PubMed',
        summary: 'Review of Tat peptide in drug delivery',
        url: 'https://pubmed.ncbi.nlm.nih.gov/20370626/',
      },
    ],
    common_adverse_effects: 'Research context; drug delivery tool',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '199',
    slug: 'transportan-10',
    name: 'Transportan-10',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Chimeric CPP combining neuropeptide galanin and wasp venom peptide sequences, enhancing cellular uptake efficiency.',
    mechanism: 'Amphipathic helix formation facilitates translocation and endosomal escape of conjugated molecules.',
    evidence: [
      {
        title: 'Transportan-10 and CPP optimization',
        year: 2004,
        source: 'PubMed',
        summary: 'Study of transportan-10 cell-penetrating properties',
        url: 'https://pubmed.ncbi.nlm.nih.gov/15583796/',
      },
    ],
    common_adverse_effects: 'Research context; drug delivery tool',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '200',
    slug: 'dermatopontin-peptides',
    name: 'Dermatopontin-Derived Peptides',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Peptide fragments from ECM protein dermatopontin that regulate fibroblast adhesion and TGF-β signaling.',
    mechanism: 'Bind integrins and modulate fibronectin fibrillogenesis, influencing scar formation.',
    evidence: [
      {
        title: 'Dermatopontin peptides and fibroblast biology',
        year: 2019,
        source: 'PubMed',
        summary: 'Study of dermatopontin in wound healing',
        url: 'https://pubmed.ncbi.nlm.nih.gov/31095166/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
  {
    id: '201',
    slug: 'collagen-tripeptide',
    name: 'Collagen Tripeptide (CTP)',
    regulatory_status: 'Research-only/Unapproved (nutritional/cosmetic use)',
    summary: 'Highly bioavailable tripeptide mixture rich in Gly-Pro-Hyp motifs used in skin and cartilage research.',
    mechanism: 'Activates fibroblast collagen gene expression and hyaluronic acid synthesis in vitro.',
    evidence: [
      {
        title: 'Collagen tripeptides and dermal health',
        year: 2018,
        source: 'PubMed',
        summary: 'Study of collagen tripeptides in skin health',
        url: 'https://pubmed.ncbi.nlm.nih.gov/29914163/',
      },
    ],
    common_adverse_effects: 'Generally well tolerated as nutritional supplement',
    contraindications: 'None specific for nutritional use',
    recommended_dosage: 'Nutritional supplement: 2.5-10 g daily',
  },
  {
    id: '202',
    slug: 'granulysin-peptides',
    name: 'Granulysin-Derived Peptides',
    regulatory_status: 'Research-only/Unapproved',
    summary: 'Fragments from immune protein granulysin studied for antimicrobial and tumoricidal activity.',
    mechanism: 'Induce membrane permeabilization in microbes and tumor cells, bridging innate and adaptive cytotoxicity.',
    evidence: [
      {
        title: 'Granulysin and peptide-based cytotoxicity',
        year: 2013,
        source: 'PubMed',
        summary: 'Study of granulysin-derived antimicrobial peptides',
        url: 'https://pubmed.ncbi.nlm.nih.gov/23939401/',
      },
    ],
    common_adverse_effects: 'Research context; not administered therapeutically',
    contraindications: 'Research context only',
    recommended_dosage: 'Research protocols only',
  },
];

export default function LibraryPage() {
  const [searchQuery, setSearchQuery] = useState('');
  const [selectedPeptide, setSelectedPeptide] = useState<any>(null);
  const [filteredPeptides, setFilteredPeptides] = useState(PEPTIDES);

  useEffect(() => {
    if (searchQuery.trim() === '') {
      setFilteredPeptides(PEPTIDES);
    } else {
      const query = searchQuery.toLowerCase();
      const filtered = PEPTIDES.filter(
        (p) =>
          p.name.toLowerCase().includes(query) ||
          p.summary.toLowerCase().includes(query) ||
          p.mechanism?.toLowerCase().includes(query)
      );
      setFilteredPeptides(filtered);
    }
  }, [searchQuery]);

  return (
    <MainLayout>
      <div className="container mx-auto px-4 py-16">
        <div className="max-w-6xl mx-auto">
          <div className="mb-8">
            <h1 className="text-4xl font-bold text-cyan-400 mb-2">Peptide Library</h1>
            <p className="text-slate-400">
              Explore our curated database of research peptides with detailed information
            </p>
          </div>

          {/* Search */}
          <div className="mb-6">
            <Input
              type="text"
              placeholder="Search peptides by name, mechanism, or summary..."
              value={searchQuery}
              onChange={(e) => setSearchQuery(e.target.value)}
              className="bg-slate-800 border-slate-600 text-slate-100 text-lg py-6"
            />
          </div>

          {/* Results */}
          <div className="grid md:grid-cols-2 gap-6">
            {/* List */}
            <div className="space-y-4">
              {filteredPeptides.map((peptide) => (
                <Card
                  key={peptide.id}
                  className={`bg-slate-800/50 border-slate-700 p-6 cursor-pointer transition-all hover:bg-slate-800/70 
                    ${selectedPeptide?.id === peptide.id ? 'border-cyan-500 bg-slate-800/70' : ''}`}
                  onClick={() => setSelectedPeptide(peptide)}
                >
                  <h3 className="text-xl font-semibold text-cyan-400 mb-2">{peptide.name}</h3>
                  <p className="text-sm text-amber-400 mb-2">{peptide.regulatory_status}</p>
                  <p className="text-slate-300 text-sm">{peptide.summary}</p>
                </Card>
              ))}

              {filteredPeptides.length === 0 && (
                <Card className="bg-slate-800/50 border-slate-700 p-6 text-center">
                  <p className="text-slate-400">No peptides found matching your search.</p>
                </Card>
              )}
            </div>

            {/* Detail Panel */}
            <div className="sticky top-4">
              {selectedPeptide ? (
                <Card className="bg-slate-800/50 border-slate-700 p-6">
                  <h2 className="text-2xl font-bold text-cyan-400 mb-2">
                    {selectedPeptide.name}
                  </h2>
                  <p className="text-amber-400 text-sm mb-4">
                    {selectedPeptide.regulatory_status}
                  </p>

                  <div className="space-y-4">
                    <div>
                      <h3 className="text-lg font-semibold text-slate-200 mb-2">Summary</h3>
                      <p className="text-slate-300 text-sm">{selectedPeptide.summary}</p>
                    </div>

                    <div>
                      <h3 className="text-lg font-semibold text-slate-200 mb-2">Mechanism</h3>
                      <p className="text-slate-300 text-sm">{selectedPeptide.mechanism}</p>
                    </div>

                    <div>
                      <h3 className="text-lg font-semibold text-slate-200 mb-2">
                        Recommended Dosage (Research)
                      </h3>
                      <p className="text-slate-300 text-sm">{selectedPeptide.recommended_dosage}</p>
                    </div>

                    <div>
                      <h3 className="text-lg font-semibold text-red-400 mb-2">
                        Common Adverse Effects
                      </h3>
                      <p className="text-slate-300 text-sm">
                        {selectedPeptide.common_adverse_effects}
                      </p>
                    </div>

                    <div>
                      <h3 className="text-lg font-semibold text-red-400 mb-2">
                        Contraindications
                      </h3>
                      <p className="text-slate-300 text-sm">{selectedPeptide.contraindications}</p>
                    </div>

                    <div>
                      <h3 className="text-lg font-semibold text-slate-200 mb-2">Evidence</h3>
                      {selectedPeptide.evidence.map((ev: any, index: number) => (
                        <div key={index} className="bg-slate-900/50 rounded-lg p-3 mb-2">
                          <p className="font-semibold text-slate-200 text-sm">
                            {ev.title} ({ev.year})
                          </p>
                          <p className="text-cyan-400 text-xs mb-1">{ev.source}</p>
                          <p className="text-slate-300 text-xs">{ev.summary}</p>
                        </div>
                      ))}
                    </div>
                  </div>

                  <div className="mt-6 p-4 bg-amber-900/20 border border-amber-700 rounded-lg">
                    <p className="text-xs text-slate-300">
                      <strong className="text-amber-400">Disclaimer:</strong> This information is for 
                      educational purposes only. Consult healthcare professionals before using any peptides.
                    </p>
                  </div>
                </Card>
              ) : (
                <Card className="bg-slate-800/50 border-slate-700 p-6 text-center">
                  <p className="text-slate-400">Select a peptide to view details</p>
                </Card>
              )}
            </div>
          </div>
        </div>
      </div>
    </MainLayout>
  );
}

